{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 8715, "items": [{"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:14:57Z", "timestamp": 1574486097026}, "reference-count": 29, "publisher": "Springer Science and Business Media LLC", "issue": "7408", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 7, 1]], "date-time": "2012-07-01T00:00:00Z", "timestamp": 1341100800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nature"], "published-print": {"date-parts": [[2012, 7]]}, "DOI": "10.1038/nature11249", "type": "journal-article", "created": {"date-parts": [[2012, 7, 4]], "date-time": "2012-07-04T20:08:00Z", "timestamp": 1341432480000}, "page": "505-509", "source": "Crossref", "is-referenced-by-count": 588, "title": ["Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors"], "prefix": "10.1038", "volume": "487", "author": [{"given": "Timothy R.", "family": "Wilson", "sequence": "first", "affiliation": []}, {"given": "Jane", "family": "Fridlyand", "sequence": "additional", "affiliation": []}, {"given": "Yibing", "family": "Yan", "sequence": "additional", "affiliation": []}, {"given": "Elicia", "family": "Penuel", "sequence": "additional", "affiliation": []}, {"given": "Luciana", "family": "Burton", "sequence": "additional", "affiliation": []}, {"given": "Emily", "family": "Chan", "sequence": "additional", "affiliation": []}, {"given": "Jing", "family": "Peng", "sequence": "additional", "affiliation": []}, {"given": "Eva", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "Yulei", "family": "Wang", "sequence": "additional", "affiliation": []}, {"given": "Jeff", "family": "Sosman", "sequence": "additional", "affiliation": []}, {"given": "Antoni", "family": "Ribas", "sequence": "additional", "affiliation": []}, {"given": "Jiang", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "John", "family": "Moffat", "sequence": "additional", "affiliation": []}, {"given": "Daniel P.", "family": "Sutherlin", "sequence": "additional", "affiliation": []}, {"given": "Hartmut", "family": "Koeppen", "sequence": "additional", "affiliation": []}, {"given": "Mark", "family": "Merchant", "sequence": "additional", "affiliation": []}, {"given": "Richard", "family": "Neve", "sequence": "additional", "affiliation": []}, {"given": "Jeff", "family": "Settleman", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 7, 4]]}, "reference": [{"key": "BFnature11249_CR1", "doi-asserted-by": "publisher", "first-page": "3214", "DOI": "10.1101/gad.1609907", "volume": "21", "author": "SV Sharma", "year": "2007", "unstructured": "Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214\u20133231 (2007)", "journal-title": "Genes Dev."}, {"key": "BFnature11249_CR2", "doi-asserted-by": "publisher", "first-page": "75ra26", "DOI": "10.1126/scitranslmed.3002003", "volume": "3", "author": "LV Sequist", "year": "2011", "unstructured": "Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011)", "journal-title": "Sci. Transl. Med."}, {"key": "BFnature11249_CR3", "doi-asserted-by": "publisher", "first-page": "793", "DOI": "10.4161/cbt.11.9.15045", "volume": "11", "author": "JT Garrett", "year": "2011", "unstructured": "Garrett, J. T. & Arteaga, C. L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 11, 793\u2013800 (2011)", "journal-title": "Cancer Biol. Ther."}, {"key": "BFnature11249_CR4", "doi-asserted-by": "publisher", "first-page": "73", "DOI": "10.1016/j.gde.2008.01.004", "volume": "18", "author": "JA Engelman", "year": "2008", "unstructured": "Engelman, J. A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73\u201379 (2008)", "journal-title": "Curr. Opin. Genet. Dev."}, {"key": "BFnature11249_CR5", "doi-asserted-by": "publisher", "first-page": "ra64", "DOI": "10.1126/scisignal.2000998", "volume": "3", "author": "A Moritz", "year": "2010", "unstructured": "Moritz, A. et al. Akt\u2013RSK\u2013S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci. Signal. 3, ra64 (2010)", "journal-title": "Sci. Signal."}, {"key": "BFnature11249_CR6", "doi-asserted-by": "publisher", "first-page": "150", "DOI": "10.4161/cbt.11.2.14623", "volume": "11", "author": "W Zhang", "year": "2011", "unstructured": "Zhang, W. & Huang, P. Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol. Ther. 11, 150\u2013156 (2011)", "journal-title": "Cancer Biol. Ther."}, {"key": "BFnature11249_CR7", "doi-asserted-by": "publisher", "first-page": "19936", "DOI": "10.1073/pnas.0707498104", "volume": "104", "author": "U McDermott", "year": "2007", "unstructured": "McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936\u201319941 (2007)", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnature11249_CR8", "doi-asserted-by": "publisher", "first-page": "158", "DOI": "10.1016/j.ccr.2011.07.011", "volume": "20", "author": "TR Wilson", "year": "2011", "unstructured": "Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S. & Settleman, J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20, 158\u2013172 (2011)", "journal-title": "Cancer Cell"}, {"key": "BFnature11249_CR9", "doi-asserted-by": "publisher", "first-page": "6963", "DOI": "10.1158/1078-0432.CCR-08-0957", "volume": "14", "author": "K Yonesaka", "year": "2008", "unstructured": "Yonesaka, K. et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin. Cancer Res. 14, 6963\u20136973 (2008)", "journal-title": "Clin. Cancer Res."}, {"key": "BFnature11249_CR10", "doi-asserted-by": "publisher", "first-page": "839", "DOI": "10.1038/nrc1477", "volume": "4", "author": "MM Mueller", "year": "2004", "unstructured": "Mueller, M. M. & Fusenig, N. E. Friends or foes \u2014 bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839\u2013849 (2004)", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnature11249_CR11", "doi-asserted-by": "publisher", "first-page": "d376", "DOI": "10.2741/grant", "volume": "7", "author": "S Grant", "year": "2002", "unstructured": "Grant, S., Qiao, L. & Dent, P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 7, d376\u2013d389 (2002)", "journal-title": "Front. Biosci."}, {"key": "BFnature11249_CR12", "doi-asserted-by": "publisher", "first-page": "1693", "DOI": "10.1056/NEJMoa1006448", "volume": "363", "author": "EL Kwak", "year": "2010", "unstructured": "Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693\u20131703 (2010)", "journal-title": "N. Engl. J. Med."}, {"key": "BFnature11249_CR13", "doi-asserted-by": "publisher", "first-page": "2507", "DOI": "10.1056/NEJMoa1103782", "volume": "364", "author": "PB Chapman", "year": "2011", "unstructured": "Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011)", "journal-title": "N. Engl. J. Med."}, {"key": "BFnature11249_CR14", "unstructured": "Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature \n                    http://dx.doi.org/10.1038/nature11183\n                    \n                   (2012)", "DOI": "10.1038/nature11183", "doi-asserted-by": "publisher"}, {"key": "BFnature11249_CR15", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1016/j.cell.2010.09.043", "volume": "143", "author": "LA Gilbert", "year": "2010", "unstructured": "Gilbert, L. A. & Hemann, M. T. DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355\u2013366 (2010)", "journal-title": "Cell"}, {"key": "BFnature11249_CR16", "doi-asserted-by": "publisher", "first-page": "423", "DOI": "10.1016/j.ccr.2010.10.025", "volume": "18", "author": "K Liang", "year": "2010", "unstructured": "Liang, K. et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18, 423\u2013435 (2010)", "journal-title": "Cancer Cell"}, {"key": "BFnature11249_CR17", "doi-asserted-by": "publisher", "first-page": "510", "DOI": "10.1016/j.ccr.2010.10.012", "volume": "18", "author": "E Quintana", "year": "2010", "unstructured": "Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510\u2013523 (2010)", "journal-title": "Cancer Cell"}, {"key": "BFnature11249_CR18", "doi-asserted-by": "publisher", "first-page": "244", "DOI": "10.1016/j.ccr.2010.12.021", "volume": "19", "author": "J Calbo", "year": "2011", "unstructured": "Calbo, J. et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19, 244\u2013256 (2011)", "journal-title": "Cancer Cell"}, {"key": "BFnature11249_CR19", "doi-asserted-by": "publisher", "first-page": "69", "DOI": "10.1016/j.cell.2010.02.027", "volume": "141", "author": "SV Sharma", "year": "2010", "unstructured": "Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010)", "journal-title": "Cell"}, {"key": "BFnature11249_CR20", "doi-asserted-by": "publisher", "first-page": "77", "DOI": "10.1016/j.ccr.2009.11.022", "volume": "17", "author": "AB Turke", "year": "2010", "unstructured": "Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77\u201388 (2010)", "journal-title": "Cancer Cell"}, {"key": "BFnature11249_CR21", "doi-asserted-by": "publisher", "first-page": "287", "DOI": "10.1126/science.1142946", "volume": "318", "author": "JM Stommel", "year": "2007", "unstructured": "Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287\u2013290 (2007)", "journal-title": "Science"}, {"key": "BFnature11249_CR22", "doi-asserted-by": "publisher", "first-page": "973", "DOI": "10.1038/nature09626", "volume": "468", "author": "R Nazarian", "year": "2010", "unstructured": "Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010)", "journal-title": "Nature"}, {"key": "BFnature11249_CR23", "first-page": "2609", "volume": "118", "author": "M Guix", "year": "2008", "unstructured": "Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609\u20132619 (2008)", "journal-title": "J. Clin. Invest."}, {"key": "BFnature11249_CR24", "doi-asserted-by": "publisher", "first-page": "1625", "DOI": "10.1158/0008-5472.CAN-09-3620", "volume": "70", "author": "U McDermott", "year": "2010", "unstructured": "McDermott, U., Pusapati, R. V., Christensen, J. G., Gray, N. S. & Settleman, J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 70, 1625\u20131634 (2010)", "journal-title": "Cancer Res."}, {"key": "BFnature11249_CR25", "doi-asserted-by": "publisher", "first-page": "968", "DOI": "10.1038/nature09627", "volume": "468", "author": "CM Johannessen", "year": "2010", "unstructured": "Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968\u2013972 (2010)", "journal-title": "Nature"}, {"key": "BFnature11249_CR26", "doi-asserted-by": "publisher", "first-page": "6871", "DOI": "10.1158/0008-5472.CAN-08-4490", "volume": "69", "author": "L Liu", "year": "2009", "unstructured": "Liu, L. et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69, 6871\u20136878 (2009)", "journal-title": "Cancer Res."}, {"key": "BFnature11249_CR27", "doi-asserted-by": "publisher", "first-page": "1039", "DOI": "10.1126/science.1141478", "volume": "316", "author": "JA Engelman", "year": "2007", "unstructured": "Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007)", "journal-title": "Science"}, {"key": "BFnature11249_CR28", "doi-asserted-by": "publisher", "first-page": "327", "DOI": "10.3109/00498254.2010.542500", "volume": "41", "author": "BM Liederer", "year": "2011", "unstructured": "Liederer, B. M. et al. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]p yridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyrida zine-4-carboxamide, a novel MET kinase inhibitor. Xenobiotica 41, 327\u2013339 (2011)", "journal-title": "Xenobiotica"}, {"key": "BFnature11249_CR29", "doi-asserted-by": "publisher", "first-page": "573", "DOI": "10.1158/2159-8290.CD-11-0175", "volume": "1", "author": "DVT Catenacci", "year": "2011", "unstructured": "Catenacci, D. V. T. et al. Durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence. Cancer Discovery 1, 573\u2013579 (2011)", "journal-title": "Cancer Discovery"}], "container-title": ["Nature"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nature11249.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nature11249", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nature11249.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 23]], "date-time": "2019-05-23T23:07:04Z", "timestamp": 1558652824000}, "score": 42.988396, "issued": {"date-parts": [[2012, 7]]}, "references-count": 29, "journal-issue": {"published-print": {"date-parts": [[2012, 7]]}, "issue": "7408"}, "alternative-id": ["BFnature11249"], "URL": "http://dx.doi.org/10.1038/nature11249", "relation": {"cites": []}, "ISSN": ["0028-0836", "1476-4687"], "issn-type": [{"value": "0028-0836", "type": "print"}, {"value": "1476-4687", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T11:08:48Z", "timestamp": 1575198528116}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "10_Supplement", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2012, 5, 15]]}, "DOI": "10.1158/1078-0432.mechres-pr6", "type": "journal-article", "created": {"date-parts": [[2013, 3, 13]], "date-time": "2013-03-13T23:55:55Z", "timestamp": 1363218955000}, "page": "PR6-PR6", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors"], "prefix": "10.1158", "volume": "18", "author": [{"given": "T. R.", "family": "Wilson", "sequence": "first", "affiliation": []}, {"given": "J.", "family": "Fridlyand", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Ribas", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Koeppen", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Merchant", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Neve", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Settleman", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Yan", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Penuel", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Burton", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Chan", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Peng", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Wang", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Sosman", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2013, 3, 4]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.MECHRES-PR6", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T03:47:59Z", "timestamp": 1482464879000}, "score": 37.356293, "issued": {"date-parts": [[2012, 5, 15]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 3, 4]]}, "published-print": {"date-parts": [[2012, 5, 15]]}, "issue": "10_Supplement"}, "URL": "http://dx.doi.org/10.1158/1078-0432.mechres-pr6", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T11:50:58Z", "timestamp": 1574423458280}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2-3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2010, 4, 1]], "date-time": "2010-04-01T00:00:00Z", "timestamp": 1270080000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cytokine & Growth Factor Reviews"], "published-print": {"date-parts": [[2010, 4]]}, "DOI": "10.1016/j.cytogfr.2010.03.002", "type": "journal-article", "created": {"date-parts": [[2010, 4, 15]], "date-time": "2010-04-15T09:03:09Z", "timestamp": 1271322189000}, "page": "153-159", "source": "Crossref", "is-referenced-by-count": 27, "title": ["Oncolytic viruses and histone deacetylase inhibitors\u2014A multi-pronged strategy to target tumor cells"], "prefix": "10.1016", "volume": "21", "author": [{"given": "Thi Lien-Anh", "family": "Nguyen", "sequence": "first", "affiliation": []}, {"given": "Marnie Goodwin", "family": "Wilson", "sequence": "additional", "affiliation": []}, {"given": "John", "family": "Hiscott", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cytokine & Growth Factor Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359610110000274?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359610110000274?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 11]], "date-time": "2018-12-11T22:51:03Z", "timestamp": 1544568663000}, "score": 23.900702, "issued": {"date-parts": [[2010, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 4]]}, "issue": "2-3"}, "alternative-id": ["S1359610110000274"], "URL": "http://dx.doi.org/10.1016/j.cytogfr.2010.03.002", "ISSN": ["1359-6101"], "issn-type": [{"value": "1359-6101", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T15:36:32Z", "timestamp": 1574436992612}, "reference-count": 39, "publisher": "Wiley", "issue": "18", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1839, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer"], "published-print": {"date-parts": [[2010, 9, 15]]}, "DOI": "10.1002/cncr.25214", "type": "journal-article", "created": {"date-parts": [[2010, 6, 14]], "date-time": "2010-06-14T20:51:50Z", "timestamp": 1276548710000}, "page": "4309-4317", "source": "Crossref", "is-referenced-by-count": 16, "title": ["Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer"], "prefix": "10.1002", "volume": "116", "author": [{"given": "Victor", "family": "Cohen", "sequence": "first", "affiliation": []}, {"given": "Jason S.", "family": "Agulnik", "sequence": "additional", "affiliation": []}, {"given": "Celina", "family": "Ang", "sequence": "additional", "affiliation": []}, {"given": "Goulnar", "family": "Kasymjanova", "sequence": "additional", "affiliation": []}, {"given": "Gerald", "family": "Batist", "sequence": "additional", "affiliation": []}, {"given": "David", "family": "Small", "sequence": "additional", "affiliation": []}, {"given": "Guilherme", "family": "Brandao", "sequence": "additional", "affiliation": []}, {"given": "George", "family": "Chong", "sequence": "additional", "affiliation": []}, {"suffix": "Jr", "given": "Wilson H.", "family": "Miller", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 8, 19]]}, "reference": [{"key": "10.1002/cncr.25214-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "2237", "DOI": "10.1200/JCO.2003.10.038", "article-title": "Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]", "volume": "21", "author": "Fukuoka", "year": "2003", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "2149", "DOI": "10.1001/jama.290.16.2149", "article-title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial", "volume": "290", "author": "Kris", "year": "2003", "journal-title": "JAMA."}, {"key": "10.1002/cncr.25214-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "3238", "DOI": "10.1200/JCO.2004.11.057", "article-title": "Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer", "volume": "22", "author": "Perez-Soler", "year": "2004", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "2129", "DOI": "10.1056/NEJMoa040938", "article-title": "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", "volume": "350", "author": "Lynch", "year": "2004", "journal-title": "N Engl J Med."}, {"key": "10.1002/cncr.25214-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1497", "DOI": "10.1126/science.1099314", "article-title": "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", "volume": "304", "author": "Paez", "year": "2004", "journal-title": "Science."}, {"key": "10.1002/cncr.25214-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "13306", "DOI": "10.1073/pnas.0405220101", "article-title": "EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib", "volume": "101", "author": "Pao", "year": "2004", "journal-title": "Proc Natl Acad Sci U S A."}, {"key": "10.1002/cncr.25214-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "8195", "DOI": "10.1158/1078-0432.CCR-04-1245", "article-title": "High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan", "volume": "10", "author": "Huang", "year": "2004", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "8919", "DOI": "10.1158/0008-5472.CAN-04-2818", "article-title": "Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications", "volume": "64", "author": "Kosaka", "year": "2004", "journal-title": "Cancer Res."}, {"key": "10.1002/cncr.25214-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "339", "DOI": "10.1093/jnci/dji055", "article-title": "Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers", "volume": "97", "author": "Shigematsu", "year": "2005", "journal-title": "J Natl Cancer Inst."}, {"key": "10.1002/cncr.25214-BIB10|cit10", "first-page": "1167", "article-title": "The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers", "volume": "11", "author": "Tokumo", "year": "2005", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "3750", "DOI": "10.1158/1078-0432.CCR-04-1981", "article-title": "Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer", "volume": "11", "author": "Chou", "year": "2005", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "1081", "DOI": "10.1093/annonc/mdi221", "article-title": "Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients", "volume": "16", "author": "Cortes-Funes", "year": "2005", "journal-title": "Ann Oncol."}, {"key": "10.1002/cncr.25214-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "2493", "DOI": "10.1200/JCO.2005.01.388", "article-title": "Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib", "volume": "23", "author": "Han", "year": "2005", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "2244", "DOI": "10.1158/1078-0432.CCR-04-2081", "article-title": "Predictors of the response to gefitinib in refractory non-small cell lung cancer", "volume": "11", "author": "Kim", "year": "2005", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "2513", "DOI": "10.1200/JCO.2005.00.992", "article-title": "Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence", "volume": "23", "author": "Mitsudomi", "year": "2005", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "4289", "DOI": "10.1158/1078-0432.CCR-04-2506", "article-title": "Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer", "volume": "11", "author": "Mu", "year": "2005", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "6829", "DOI": "10.1200/JCO.2005.01.0793", "article-title": "Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer", "volume": "23", "author": "Takano", "year": "2005", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "5878", "DOI": "10.1158/1078-0432.CCR-04-2618", "article-title": "Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas", "volume": "11", "author": "Taron", "year": "2005", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "1334", "DOI": "10.1093/annonc/mdi340", "article-title": "The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer", "volume": "16", "author": "Zhang", "year": "2005", "journal-title": "Ann Oncol."}, {"key": "10.1002/cncr.25214-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "7232", "DOI": "10.1158/1078-0432.CCR-06-0658", "article-title": "Update on epidermal growth factor receptor mutations in non-small cell lung cancer", "volume": "12", "author": "Riely", "year": "2006", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "3340", "DOI": "10.1200/JCO.2005.05.4692", "article-title": "Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations", "volume": "24", "author": "Inoue", "year": "2006", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "1028", "DOI": "10.1093/annonc/mdj114", "article-title": "EGFR mutation in gefitinib-responsive small-cell lung cancer", "volume": "17", "author": "Okamoto", "year": "2006", "journal-title": "Ann Oncol."}, {"key": "10.1002/cncr.25214-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "383", "DOI": "10.1016/j.lungcan.2007.01.025", "article-title": "Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy", "volume": "56", "author": "Sunaga", "year": "2007", "journal-title": "Lung Cancer."}, {"key": "10.1002/cncr.25214-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "7504", "DOI": "10.1200/JCO.2006.07.3585", "article-title": "iTARGET: a phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors [abstract]", "volume": "25", "author": "Sequist", "year": "2007", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "3908", "DOI": "10.1158/1078-0432.CCR-06-0462", "article-title": "Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib", "volume": "12", "author": "Jackman", "year": "2006", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1158/1078-0432.CCR-05-1846", "article-title": "Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib", "volume": "12", "author": "Riely", "year": "2006", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "2858", "DOI": "10.1002/cncr.22331", "article-title": "Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer", "volume": "107", "author": "Cohen", "year": "2006", "journal-title": "Cancer."}, {"key": "10.1002/cncr.25214-BIB28|cit28", "first-page": "891", "article-title": "The detection by denaturing high performance liquid chromatography of epidermal growth factor receptor mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer [in Chinese]", "volume": "31", "author": "Bai", "year": "2008", "journal-title": "Zhonghua Jie He He Hu Xi Za Zhi."}, {"key": "10.1002/cncr.25214-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "2106", "DOI": "10.1158/1078-0432.CCR-04-1853", "article-title": "Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer", "volume": "11", "author": "Yang", "year": "2005", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.1378/chest.128.1.317", "article-title": "Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer", "volume": "128", "author": "Hsieh", "year": "2005", "journal-title": "Chest."}, {"key": "10.1002/cncr.25214-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "554", "DOI": "10.1038/ncponc0341", "article-title": "EGFR inhibitors: what have we learned from the treatment of lung cancer?", "volume": "2", "author": "Giaccone", "year": "2005", "journal-title": "Nat Clin Pract Oncol."}, {"key": "10.1002/cncr.25214-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "1103", "DOI": "10.1200/JCO.2004.08.158", "article-title": "Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer", "volume": "22", "author": "Miller", "year": "2004", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "5892", "DOI": "10.1200/JCO.2005.02.840", "article-title": "TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer", "volume": "23", "author": "Herbst", "year": "2005", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "947", "DOI": "10.1056/NEJMoa0810699", "article-title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", "volume": "361", "author": "Mok", "year": "2009", "journal-title": "N Engl J Med."}, {"key": "10.1002/cncr.25214-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "2745", "DOI": "10.1200/JCO.2007.15.6695", "article-title": "Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy", "volume": "26", "author": "Yang", "year": "2008", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25214-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "7060", "DOI": "10.1158/1078-0432.CCR-08-1455", "article-title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib", "volume": "14", "author": "Costa", "year": "2008", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1016/j.canlet.2008.02.064", "article-title": "Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is because of differential inhibition of downstream signals", "volume": "265", "author": "Zhu", "year": "2008", "journal-title": "Cancer Lett."}, {"key": "10.1002/cncr.25214-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "6494", "DOI": "10.1158/1078-0432.CCR-06-1570", "article-title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors", "volume": "12", "author": "Balak", "year": "2006", "journal-title": "Clin Cancer Res."}, {"key": "10.1002/cncr.25214-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "998", "DOI": "10.1038/sj.bjc.6603393", "article-title": "A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations", "volume": "95", "author": "Asahina", "year": "2006", "journal-title": "Br J Cancer."}], "container-title": ["Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25214", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 1]], "date-time": "2019-03-01T08:05:24Z", "timestamp": 1551427524000}, "score": 23.511019, "subtitle": ["Impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors"], "issued": {"date-parts": [[2010, 8, 19]]}, "references-count": 39, "journal-issue": {"published-print": {"date-parts": [[2010, 9, 15]]}, "issue": "18"}, "URL": "http://dx.doi.org/10.1002/cncr.25214", "relation": {"cites": []}, "ISSN": ["0008-543X"], "issn-type": [{"value": "0008-543X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T07:50:17Z", "timestamp": 1574495417710}, "reference-count": 60, "publisher": "Springer Science and Business Media LLC", "issue": "25", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 8, 6]], "date-time": "2012-08-06T00:00:00Z", "timestamp": 1344211200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncogene"], "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1038/onc.2012.319", "type": "journal-article", "created": {"date-parts": [[2012, 8, 6]], "date-time": "2012-08-06T15:35:07Z", "timestamp": 1344267307000}, "page": "3059-3070", "source": "Crossref", "is-referenced-by-count": 51, "title": ["Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance"], "prefix": "10.1038", "volume": "32", "author": [{"given": "V", "family": "Chell", "sequence": "first", "affiliation": []}, {"given": "K", "family": "Balmanno", "sequence": "additional", "affiliation": []}, {"given": "A S", "family": "Little", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Wilson", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Andrews", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Blockley", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Hampson", "sequence": "additional", "affiliation": []}, {"given": "P R", "family": "Gavine", "sequence": "additional", "affiliation": []}, {"given": "S J", "family": "Cook", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 8, 6]]}, "reference": [{"key": "BFonc2012319_CR1", "doi-asserted-by": "publisher", "first-page": "D165", "DOI": "10.2741/Klint", "volume": "4", "author": "P Klint", "year": "1999", "unstructured": "Klint P, Claesson-Welsh L . Signal transduction by fibroblast growth factor receptors. Front Biosci 1999; 4: D165\u2013D177.", "journal-title": "Front Biosci"}, {"key": "BFonc2012319_CR2", "doi-asserted-by": "publisher", "first-page": "139", "DOI": "10.1016/j.cytogfr.2005.01.001", "volume": "16", "author": "VP Eswarakumar", "year": "2005", "unstructured": "Eswarakumar VP, Lax I, Schlessinger J . Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139\u2013149.", "journal-title": "Cytokine Growth Factor Rev"}, {"key": "BFonc2012319_CR3", "doi-asserted-by": "publisher", "first-page": "1446", "DOI": "10.1101/gad.990702", "volume": "16", "author": "DM Ornitz", "year": "2002", "unstructured": "Ornitz DM, Marie PJ . FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002; 16: 1446\u20131465.", "journal-title": "Genes Dev"}, {"key": "BFonc2012319_CR4", "doi-asserted-by": "publisher", "first-page": "12040", "DOI": "10.1074/jbc.M109006200", "volume": "277", "author": "OE Pardo", "year": "2002", "unstructured": "Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ et al. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. J Biol Chem 2002; 277: 12040\u201312046.", "journal-title": "J Biol Chem"}, {"key": "BFonc2012319_CR5", "doi-asserted-by": "publisher", "first-page": "469", "DOI": "10.1517/14728222.6.4.469", "volume": "6", "author": "M Jeffers", "year": "2002", "unstructured": "Jeffers M, LaRochelle WJ, Lichenstein HS . Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 2002; 6: 469\u2013482.", "journal-title": "Expert Opin Ther Targets"}, {"key": "BFonc2012319_CR6", "doi-asserted-by": "publisher", "first-page": "105", "DOI": "10.1016/j.pharmthera.2009.10.001", "volume": "125", "author": "V Knights", "year": "2010", "unstructured": "Knights V, Cook SJ . De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125: 105\u2013117.", "journal-title": "Pharmacol Ther"}, {"key": "BFonc2012319_CR7", "doi-asserted-by": "publisher", "first-page": "2289", "DOI": "10.1080/10428190600822128", "volume": "47", "author": "JJ Keats", "year": "2006", "unstructured": "Keats JJ, Reiman T, Belch AR, Pilarski LM . Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006; 47: 2289\u20132300.", "journal-title": "Leuk Lymphoma"}, {"key": "BFonc2012319_CR8", "first-page": "3541", "volume": "61", "author": "JH Jang", "year": "2001", "unstructured": "Jang JH, Shin KH, Park JG . Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61: 3541\u20133543.", "journal-title": "Cancer Res"}, {"key": "BFonc2012319_CR9", "doi-asserted-by": "publisher", "first-page": "40", "DOI": "10.1158/0008-5472.CAN-03-1022", "volume": "64", "author": "ME Ray", "year": "2004", "unstructured": "Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA et al. Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 2004; 64: 40\u201347.", "journal-title": "Cancer Res"}, {"key": "BFonc2012319_CR10", "doi-asserted-by": "publisher", "first-page": "1955", "DOI": "10.1016/S0002-9440(10)64665-2", "volume": "158", "author": "C Billerey", "year": "2001", "unstructured": "Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955\u20131959.", "journal-title": "Am J Pathol"}, {"key": "BFonc2012319_CR11", "first-page": "1735", "volume": "92", "author": "A Reiter", "year": "1998", "unstructured": "Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998; 92: 1735\u20131742.", "journal-title": "Blood"}, {"key": "BFonc2012319_CR12", "first-page": "643", "volume": "2", "author": "AB Moffa", "year": "2004", "unstructured": "Moffa AB, Tannheimer SL, Ethier SP . Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004; 2: 643\u2013652.", "journal-title": "Mol Cancer Res"}, {"key": "BFonc2012319_CR13", "doi-asserted-by": "publisher", "first-page": "2045", "DOI": "10.1158/0008-5472.CAN-11-3034", "volume": "72", "author": "PR Gavine", "year": "2012", "unstructured": "Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S et al. AZD4547: an orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72: 2045\u20132056.", "journal-title": "Cancer Res"}, {"key": "BFonc2012319_CR14", "author": "T Klinowska", "year": "2008", "unstructured": "Klinowska T, Gavine PR, Mooney L, Parveen N, Al-Kadhimi K, Thomas A et al. The characterization of novel, potent and selective small molecule inhibitors of the FGFR tyrosine kinase in vitro and in vivo. Gordon Research Conference 2\u20137 March 2008; Lucca, Italy.", "volume-title": "Gordon Research Conference"}, {"key": "BFonc2012319_CR15", "first-page": "13369", "volume": "267", "author": "C Kahan", "year": "1992", "unstructured": "Kahan C, Seuwen K, Meloche S, Pouyss\u00e9gur J . Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. J Biol Chem 1992; 267: 13369\u201313375.", "journal-title": "J Biol Chem"}, {"key": "BFonc2012319_CR16", "doi-asserted-by": "publisher", "first-page": "3077", "DOI": "10.1158/0008-5472.CAN-07-3293", "volume": "68", "author": "IB Weinstein", "year": "2008", "unstructured": "Weinstein IB, Joe A . Oncogene addiction. Cancer Res 2008; 68: 3077\u20133080.", "journal-title": "Cancer Res"}, {"key": "BFonc2012319_CR17", "doi-asserted-by": "publisher", "first-page": "729", "DOI": "10.1182/blood.V97.3.729", "volume": "97", "author": "M Chesi", "year": "2001", "unstructured": "Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729\u2013736.", "journal-title": "Blood"}, {"key": "BFonc2012319_CR18", "doi-asserted-by": "publisher", "first-page": "3521", "DOI": "10.1182/blood-2003-10-3650", "volume": "103", "author": "S Trudel", "year": "2004", "unstructured": "Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103: 3521\u20133528.", "journal-title": "Blood"}, {"key": "BFonc2012319_CR19", "doi-asserted-by": "publisher", "first-page": "226", "DOI": "10.1002/gcc.20404", "volume": "46", "author": "L Lombardi", "year": "2007", "unstructured": "Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226\u2013238.", "journal-title": "Genes Chromosomes Cancer"}, {"key": "BFonc2012319_CR20", "doi-asserted-by": "publisher", "first-page": "3553", "DOI": "10.1038/sj.onc.1204465", "volume": "20", "author": "D Ronchetti", "year": "2001", "unstructured": "Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553\u20133562.", "journal-title": "Oncogene"}, {"key": "BFonc2012319_CR21", "doi-asserted-by": "publisher", "first-page": "2555", "DOI": "10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M", "volume": "92", "author": "T Kimura", "year": "2001", "unstructured": "Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y . The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001; 92: 2555\u20132561.", "journal-title": "Cancer"}, {"key": "BFonc2012319_CR22", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1002/path.2207", "volume": "213", "author": "DC Tomlinson", "year": "2007", "unstructured": "Tomlinson DC, Baldo O, Harnden P, Knowles MA . FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91\u201398.", "journal-title": "J Pathol"}, {"key": "BFonc2012319_CR23", "doi-asserted-by": "publisher", "first-page": "270", "DOI": "10.1002/path.2892", "volume": "224", "author": "HA Al-Ahmadie", "year": "2011", "unstructured": "Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol 2011; 224: 270\u2013279.", "journal-title": "J Pathol"}, {"key": "BFonc2012319_CR24", "doi-asserted-by": "publisher", "first-page": "5889", "DOI": "10.1038/sj.onc.1210399", "volume": "26", "author": "DC Tomlinson", "year": "2007", "unstructured": "Tomlinson DC, Hurst CD, Knowles MA . Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007; 26: 5889\u20135899.", "journal-title": "Oncogene"}, {"key": "BFonc2012319_CR25", "doi-asserted-by": "publisher", "first-page": "2013", "DOI": "10.1038/onc.2009.489", "volume": "29", "author": "N Turner", "year": "2010", "unstructured": "Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013\u20132023.", "journal-title": "Oncogene"}, {"key": "BFonc2012319_CR26", "doi-asserted-by": "publisher", "first-page": "773", "DOI": "10.1002/jso.22120", "volume": "105", "author": "S Sun", "year": "2011", "unstructured": "Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 2011; 105: 773\u2013779.", "journal-title": "J Surg Oncol"}, {"key": "BFonc2012319_CR27", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1186/bcr73", "volume": "2", "author": "SL Tannheimer", "year": "2000", "unstructured": "Tannheimer SL, Rehemtulla A, Ethier SP . Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000; 2: 311\u2013320.", "journal-title": "Breast Cancer Res"}, {"key": "BFonc2012319_CR28", "doi-asserted-by": "publisher", "first-page": "5983", "DOI": "10.1073/pnas.87.15.5983", "volume": "87", "author": "Y Hattori", "year": "1990", "unstructured": "Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA 1990; 87: 5983\u20135987.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFonc2012319_CR29", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1016/0006-291X(92)91548-5", "volume": "189", "author": "H Kuniyasu", "year": "1992", "unstructured": "Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E . Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189: 227\u2013232.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "BFonc2012319_CR30", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1007/s004280050115", "volume": "431", "author": "H Tsujimoto", "year": "1997", "unstructured": "Tsujimoto H, Sugihara H, Hagiwara A, Hattori T . Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997; 431: 383\u2013389.", "journal-title": "Virchows Arch"}, {"key": "BFonc2012319_CR31", "doi-asserted-by": "publisher", "first-page": "111", "DOI": "10.1016/0165-4608(93)90217-A", "volume": "65", "author": "O Mor", "year": "1993", "unstructured": "Mor O, Ranzani GN, Ravia Y, Rotman G, Gutman M, Manor A et al. DNA amplification in human gastric carcinomas. Cancer Genet Cytogenet 1993; 65: 111\u2013114.", "journal-title": "Cancer Genet Cytogenet"}, {"key": "BFonc2012319_CR32", "doi-asserted-by": "publisher", "first-page": "2340", "DOI": "10.1158/0008-5472.CAN-07-5229", "volume": "68", "author": "K Kunii", "year": "2008", "unstructured": "Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340\u20132348.", "journal-title": "Cancer Res"}, {"key": "BFonc2012319_CR33", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1038/nrclinonc.2010.97", "volume": "7", "author": "DL Wheeler", "year": "2010", "unstructured": "Wheeler DL, Dunn EF, Harari PM . Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493\u2013507.", "journal-title": "Nat Rev Clin Oncol"}, {"key": "BFonc2012319_CR34", "doi-asserted-by": "publisher", "first-page": "7519", "DOI": "10.1158/1078-0432.CCR-09-1068", "volume": "15", "author": "D Milojkovic", "year": "2009", "unstructured": "Milojkovic D, Apperley J . Mechanisms of resistance to imatinib and second- generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 7519\u20137527.", "journal-title": "Clin Cancer Res"}, {"key": "BFonc2012319_CR35", "doi-asserted-by": "publisher", "first-page": "7502", "DOI": "10.1158/1078-0432.CCR-09-0189", "volume": "15", "author": "PS Hammerman", "year": "2009", "unstructured": "Hammerman PS, Janne PA, Johnson BE . Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15: 7502\u20137509.", "journal-title": "Clin Cancer Res"}, {"key": "BFonc2012319_CR36", "doi-asserted-by": "publisher", "first-page": "18811", "DOI": "10.1074/jbc.M301010200", "volume": "278", "author": "R Ley", "year": "2003", "unstructured": "Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ . Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811\u201318816.", "journal-title": "J Biol Chem"}, {"key": "BFonc2012319_CR37", "doi-asserted-by": "publisher", "first-page": "2856", "DOI": "10.1038/sj.emboj.7601723", "volume": "26", "author": "KE Ewings", "year": "2007", "unstructured": "Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R et al. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 2007; 26: 2856\u20132867.", "journal-title": "EMBO J"}, {"key": "BFonc2012319_CR38", "doi-asserted-by": "publisher", "first-page": "1109", "DOI": "10.1038/nsmb.1486", "volume": "15", "author": "M Azam", "year": "2008", "unstructured": "Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ . Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 1109\u20131118.", "journal-title": "Nat Struct Mol Biol"}, {"key": "BFonc2012319_CR39", "doi-asserted-by": "publisher", "first-page": "1001", "DOI": "10.1038/nrd1579", "volume": "3", "author": "H Daub", "year": "2004", "unstructured": "Daub H, Specht K, Ullrich A . Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001\u20131010.", "journal-title": "Nat Rev Drug Discov"}, {"key": "BFonc2012319_CR40", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1007/BF03256446", "volume": "10", "author": "M Azam", "year": "2006", "unstructured": "Azam M, Daley GQ . Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006; 10: 67\u201376.", "journal-title": "Mol Diagn Ther"}, {"key": "BFonc2012319_CR41", "doi-asserted-by": "publisher", "first-page": "5896", "DOI": "10.1093/emboj/17.20.5896", "volume": "17", "author": "M Mohammadi", "year": "1998", "unstructured": "Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17: 5896\u20135904.", "journal-title": "EMBO J"}, {"key": "BFonc2012319_CR42", "doi-asserted-by": "publisher", "first-page": "1216", "DOI": "10.1172/JCI38017", "volume": "119", "author": "J Qing", "year": "2009", "unstructured": "Qing J, Du X, Chen Y, Chan P, Li H, Wu P et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119: 1216\u20131229.", "journal-title": "J Clin Invest"}, {"key": "BFonc2012319_CR43", "doi-asserted-by": "publisher", "first-page": "1542", "DOI": "10.1158/1535-7163.MCT-11-0426", "volume": "10", "author": "M Squires", "year": "2011", "unstructured": "Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P et al. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther 2011; 10: 1542\u20131552.", "journal-title": "Mol Cancer Ther"}, {"key": "BFonc2012319_CR44", "doi-asserted-by": "publisher", "first-page": "2941", "DOI": "10.1182/blood-2004-10-3913", "volume": "105", "author": "S Trudel", "year": "2005", "unstructured": "Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941\u20132948.", "journal-title": "Blood"}, {"key": "BFonc2012319_CR45", "doi-asserted-by": "publisher", "first-page": "75", "DOI": "10.1038/sj.bjc.6606016", "volume": "104", "author": "FR Lamont", "year": "2011", "unstructured": "Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA . Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75\u201382.", "journal-title": "Br J Cancer"}, {"key": "BFonc2012319_CR46", "doi-asserted-by": "publisher", "first-page": "5218", "DOI": "10.1038/sj.onc.1208705", "volume": "24", "author": "AH Jebar", "year": "2005", "unstructured": "Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, MA Knowles . FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218\u20135225.", "journal-title": "Oncogene"}, {"key": "BFonc2012319_CR47", "doi-asserted-by": "publisher", "first-page": "519", "DOI": "10.1038/nrclinonc.2009.111", "volume": "6", "author": "N Normanno", "year": "2009", "unstructured": "Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F . Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519\u2013527.", "journal-title": "Nat Rev Clin Oncol"}, {"key": "BFonc2012319_CR48", "doi-asserted-by": "publisher", "first-page": "285", "DOI": "10.1016/j.chembiol.2010.02.007", "volume": "17", "author": "W Zhou", "year": "2010", "unstructured": "Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB et al. A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol 2010; 17: 285\u2013295.", "journal-title": "Chem Biol"}, {"key": "BFonc2012319_CR49", "doi-asserted-by": "publisher", "first-page": "6146", "DOI": "10.1158/1078-0432.CCR-08-0509", "volume": "14", "author": "H Huynh", "year": "2008", "unstructured": "Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146\u20136153.", "journal-title": "Clin Cancer Res"}, {"key": "BFonc2012319_CR50", "doi-asserted-by": "publisher", "first-page": "4774", "DOI": "10.1158/0008-5472.CAN-07-6307", "volume": "68", "author": "F Hilberg", "year": "2008", "unstructured": "Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774\u20134782.", "journal-title": "Cancer Res"}, {"key": "BFonc2012319_CR51", "doi-asserted-by": "publisher", "first-page": "371", "DOI": "10.1084/jem.20052242", "volume": "203", "author": "HS Radomska", "year": "2006", "unstructured": "Radomska HS, Bass\u00e8res DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006; 203: 371\u2013381.", "journal-title": "J Exp Med"}, {"key": "BFonc2012319_CR52", "doi-asserted-by": "publisher", "first-page": "444", "DOI": "10.1038/86515", "volume": "7", "author": "T Pabst", "year": "2001", "unstructured": "Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444\u2013451.", "journal-title": "Nat Med"}, {"key": "BFonc2012319_CR53", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1038/332083a0", "volume": "332", "author": "M Kawano", "year": "1988", "unstructured": "Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83\u201385.", "journal-title": "Nature"}, {"key": "BFonc2012319_CR54", "doi-asserted-by": "publisher", "first-page": "657", "DOI": "10.3892/mmr_00000153", "volume": "2", "author": "R Binato", "year": "2009", "unstructured": "Binato R, Mencalha A, Pizzatti L, Scholl V, Zalcberg I, Abdelhay E . RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Mol Med Rep 2009; 2: 657\u2013661.", "journal-title": "Mol Med Rep"}, {"key": "BFonc2012319_CR55", "doi-asserted-by": "publisher", "first-page": "3284", "DOI": "10.1038/sj.onc.1207467", "volume": "23", "author": "DE Todd", "year": "2004", "unstructured": "Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR et al. ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene 2004; 23: 3284\u20133295.", "journal-title": "Oncogene"}, {"key": "BFonc2012319_CR56", "doi-asserted-by": "publisher", "first-page": "2209", "DOI": "10.1158/1535-7163.MCT-07-0231", "volume": "6", "author": "BR Davies", "year": "2007", "unstructured": "Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6: 2209\u20132219.", "journal-title": "Mol Cancer Ther"}, {"key": "BFonc2012319_CR57", "doi-asserted-by": "publisher", "first-page": "1189", "DOI": "10.1093/bioinformatics/btp033", "volume": "25", "author": "AM Waterhouse", "year": "2009", "unstructured": "Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ . Jalview Version 2 a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009; 25: 1189\u20131191.", "journal-title": "Bioinformatics"}, {"key": "BFonc2012319_CR58", "doi-asserted-by": "publisher", "first-page": "486", "DOI": "10.1107/S0907444910007493", "volume": "66", "author": "P Emsley", "year": "2010", "unstructured": "Emsley P, Lohkamp B, Scott WG, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010; 66: 486\u2013501.", "journal-title": "Acta Crystallogr D Biol Crystallogr"}, {"key": "BFonc2012319_CR59", "first-page": "289", "volume": "57", "author": "Y Benjamini", "year": "1995", "unstructured": "Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995; 57: 289\u2013300.", "journal-title": "J Roy Statist Soc Ser B (Methodological)"}, {"issue": "7", "key": "BFonc2012319_CR60", "doi-asserted-by": "publisher", "first-page": "research0034.1", "DOI": "10.1186/gb-2002-3-7-research0034", "volume": "3", "author": "Jo Vandesompele", "year": "2002", "unstructured": "Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: : RESEARCH0034.", "journal-title": "Genome Biology"}], "container-title": ["Oncogene"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/onc2012319.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/onc2012319", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/onc2012319.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 19]], "date-time": "2019-04-19T14:20:48Z", "timestamp": 1555683648000}, "score": 23.140543, "issued": {"date-parts": [[2012, 8, 6]]}, "references-count": 60, "journal-issue": {"published-print": {"date-parts": [[2013, 6]]}, "issue": "25"}, "alternative-id": ["BFonc2012319"], "URL": "http://dx.doi.org/10.1038/onc.2012.319", "relation": {"cites": []}, "ISSN": ["0950-9232", "1476-5594"], "issn-type": [{"value": "0950-9232", "type": "print"}, {"value": "1476-5594", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T17:28:30Z", "timestamp": 1574530110460}, "publisher-location": "Boston, MA", "reference-count": 53, "publisher": "Springer US", "isbn-type": [{"value": "9780306444845", "type": "print"}, {"value": "9781461528463", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1993]]}, "DOI": "10.1007/978-1-4615-2846-3_28", "type": "book-chapter", "created": {"date-parts": [[2011, 7, 27]], "date-time": "2011-07-27T01:36:49Z", "timestamp": 1311730609000}, "page": "297-308", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Structure-Function Analysis of Fibroblast Growth Factor-1 (Acidic Fibroblast Growth Factor)"], "prefix": "10.1007", "author": [{"given": "Wilson H.", "family": "Burgess", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "28_CR1", "doi-asserted-by": "publisher", "first-page": "xi", "DOI": "10.1111/j.1749-6632.1991.tb49010.x", "volume": "638", "author": "A. Baird", "year": "1991", "unstructured": "A. Baird and M. Klagsbrun, The fibroblast growth factor family an overview, Annals N.Y. Acad. Sci. 638:xi (1991).", "journal-title": "Annals N.Y. Acad. Sci"}, {"key": "28_CR2", "doi-asserted-by": "publisher", "first-page": "1385", "DOI": "10.1126/science.4071057", "volume": "230", "author": "G. Gimenez-Gallego", "year": "1985", "unstructured": "G. Gimenez-Gallego, J. Rodkey, C. Bennet, M. Rios-Candelore, J. DiSalvo and K. Thomas, Brain-derived acidic fibroblast growth factor: complete amino acid sequence and homologies, Science 230:1385 (1985).", "journal-title": "Science"}, {"key": "28_CR3", "doi-asserted-by": "publisher", "first-page": "4988", "DOI": "10.1021/bi00366a003", "volume": "25", "author": "J.W. Crabb", "year": "1986", "unstructured": "J.W. Crabb, L.G. Armes, S.A. Carr, C.M. Johnson, G.D. Robert, R.S. Bordolic and W.L. McKeehan, Complete primary structure of prostatropin, a prostate epithelial cell growth factor, Biochemistry 25:4988 (1986).", "journal-title": "Biochemistry"}, {"key": "28_CR4", "doi-asserted-by": "publisher", "first-page": "7216", "DOI": "10.1073/pnas.83.19.7216", "volume": "83", "author": ".H. Burgess", "year": "1986", "unstructured": "W.H. Burgess, T. Mehlman, D.R. Marshak, B.A. Fraser and T. Maciag, Structural evidence that endothelial cell growth factor-\u00df is the precursor of both endothelial cell growth factor-\u03b1 and acidic fibroblast growth factor, Proc. Natl. Acad. Sci. USA 83:7216 (1986).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "28_CR5", "doi-asserted-by": "publisher", "first-page": "541", "DOI": "10.1126/science.3523756", "volume": "233", "author": "M. Jaye", "year": "1986", "unstructured": "M. Jaye, R. Howk, W.H. Burgess, G.A. Ricca, I.-M. Chiu, M.W. Rayera, S.J. O\u2019Brien, W.S. Modi, T. Maciag and W.N. Drohan, Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization, Science 233:541 (1986).", "journal-title": "Science"}, {"key": "28_CR6", "doi-asserted-by": "publisher", "first-page": "10913", "DOI": "10.1093/nar/16.22.10913", "volume": "16", "author": "C.Y. Halley", "year": "1988", "unstructured": "C.Y. Halley, Y. Courtois and M. Laurent, Nucleotide sequence of bovine acidic fibroblast growth factor cDNA, Nucleic Acids Res. 16:10913 (1988).", "journal-title": "Nucleic Acids Res"}, {"key": "28_CR7", "unstructured": "T. Mehlman and W.H. Burgess (Manuscript in preparation)."}, {"key": "28_CR8", "doi-asserted-by": "publisher", "first-page": "2867", "DOI": "10.1093/nar/17.7.2867", "volume": "17", "author": "S.P. Goodrich", "year": "1989", "unstructured": "S.P. Goodrich, G.-C. Yan, K. Bahrenburg and P.-E. Mansson, The nucleotide sequence of rat heparin binding growth factor-1 (HBGF-1), Nucleic Acids Res. 17:2867 (1989).", "journal-title": "Nucleic Acids Res"}, {"key": "28_CR9", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1002/jcb.240430103", "volume": "43", "author": "J.A. Hall", "year": "1990", "unstructured": "J.A. Hall, M.A. Harris, M. Malark, P.-E. Mansson, H. Zhou and S.E. Harris, Characterization of the hamster DDT-1 cell afgf/HBGF-1 gene and cDNA and its modulation by steroids, J. Cell. Biochem. 43:17 (1990).", "journal-title": "J. Cell. Biochem."}, {"key": "28_CR10", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.1111/j.1749-6632.1991.tb49020.x", "volume": "638", "author": "W.H. Burgess", "year": "1991", "unstructured": "W.H. Burgess, Struture-function studies of acidic fibroblast growth factor, Annals N.Y. Acad. Sci., 638:89 (1991).", "journal-title": "Annals N.Y. Acad. Sci."}, {"key": "28_CR11", "doi-asserted-by": "publisher", "first-page": "1296", "DOI": "10.1126/science.6199844", "volume": "223", "author": "Y. Shing", "year": "1984", "unstructured": "Y. Shing, J. Folkman, R. Sullivan, C. Butterfield, J. Murray and M. Klagsbrun, Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor, Science 223:1296 (1984).", "journal-title": "Science"}, {"key": "28_CR12", "doi-asserted-by": "publisher", "first-page": "6295", "DOI": "10.1021/bi00321a001", "volume": "23", "author": "R.R. Lobb", "year": "1984", "unstructured": "R.R. Lobb and J.W. Fett, Purification of two distinct growth factors from bovine neural tissue by heparin affinity chromatography, Biochemistry 23:6295 (1984).", "journal-title": "Biochemistry"}, {"key": "28_CR13", "first-page": "11389", "volume": "260", "author": "W.H. Burgess", "year": "1985", "unstructured": "W.H. Burgess, T. Mehlman, R. Friesel, W. Johnson and T. Maciag, Multiple forms of endothelial cell growth factor, J. Biol. Chem. 260:11389 (1985).", "journal-title": "J. Biol. Chem."}, {"key": "28_CR14", "doi-asserted-by": "publisher", "first-page": "575", "DOI": "10.1146/annurev.bi.58.070189.003043", "volume": "58", "author": "W.H. Burgess", "year": "1989", "unstructured": "W.H. Burgess and T. Maciag, The heparin-binding (fibroblast) growth factor family of proteins, Annu. Rev. Biochem. 58:575 (1989).", "journal-title": "Annu. Rev. Biochem."}, {"key": "28_CR15", "doi-asserted-by": "publisher", "first-page": "207", "DOI": "10.1016/0955-2235(89)90012-4", "volume": "1", "author": "M. Klagsbrun", "year": "1989", "unstructured": "M. Klagsbrun, The fibroblast growth factor family: structural and biological properties, Prog. Growth Factor Res. 1:207 (1989).", "journal-title": "Prog. Growth Factor Res."}, {"key": "28_CR16", "doi-asserted-by": "publisher", "first-page": "6138", "DOI": "10.1073/pnas.82.18.6138", "volume": "82", "author": "A.B. Schreiber", "year": "1985", "unstructured": "A.B. Schreiber, J. Kenney, W.J. Kowalski, R. Friesel, T. Mehlman and T. Maciag, Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition, Proc. Natl. Acad. Sci. USA 82:6138 (1985).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "28_CR17", "doi-asserted-by": "publisher", "first-page": "107", "DOI": "10.1016/S0006-291X(05)80179-2", "volume": "172", "author": "J.M. Kaplow", "year": "1990", "unstructured": "J.M. Kaplow, F. Bellot, G. Crumley, C.A. Dionne and M. Jaye, Effect of heparin on the binding affinity of acidic fgf for the cloned human fgf receptors, flg and bek, Biochem. Biophys. Res. Comm. 172:107\u2013112 (1990).", "journal-title": "Biochem. Biophys. Res. Comm."}, {"key": "28_CR18", "doi-asserted-by": "publisher", "first-page": "432", "DOI": "10.1016/S0006-291X(88)80732-0", "volume": "152", "author": "T.K. Rosengart", "year": "1988", "unstructured": "T.K. Rosengart, W.V. Johnson, R. Friesel, T. Mehlman and T. Maciag, Heparin protects heparin-binding growth factor-1 from proteolytic inactivation in vitro, Biochem. Biophys. Res. Comm. 152:432 (1988).", "journal-title": "Biochem. Biophys. Res. Comm."}, {"key": "28_CR19", "doi-asserted-by": "publisher", "first-page": "743", "DOI": "10.1083/jcb.107.2.743", "volume": "107", "author": "O. Saksela", "year": "1988", "unstructured": "O. Saksela, D. Moscatelli, A. Sommer and D.B. Rifkin, Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation, J. Cell Biol. 107:743 (1988).", "journal-title": "J. Cell Biol."}, {"key": "28_CR20", "doi-asserted-by": "publisher", "first-page": "2572", "DOI": "10.1021/bi00407a045", "volume": "27", "author": "R.R. Lobb", "year": "1988", "unstructured": "R.R. Lobb, Thrombin inactivates acidic fibroblast growth factor but not basic fibroblast growth factor, Biochemistry 27:2572 (1988).", "journal-title": "Biochemistry"}, {"key": "28_CR21", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.1002/jcp.1041280317", "volume": "128", "author": "D. Gospodarowicz", "year": "1986", "unstructured": "D. Gospodarowicz and J. Cheng, Heparin protects basic and acidic fgf from inactivation, J. Cell Physiol. 128:475 (1986).", "journal-title": "J. Cell Physiol."}, {"key": "28_CR22", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1016/0167-4889(92)90136-Y", "volume": "1135", "author": "M. Jaye", "year": "1992", "unstructured": "M. Jaye, J. Schlessinger and C.A. Dionne, Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction, Biochem. Biophys. Acta. 1135:185 (1992).", "journal-title": "Biochem. Biophys. Acta."}, {"key": "28_CR23", "doi-asserted-by": "publisher", "first-page": "246", "DOI": "10.1073/pnas.89.1.246", "volume": "89", "author": "T. Mild", "year": "1992", "unstructured": "T. Mild, D.P. Bottaro, T.P. Fleming, C.L. Smith, W.H. Burgess, A.M.-L. Chan and S.A. Aaronson, Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene, Proc. Natl. Acad. Sci. USA 89:246 (1992).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "28_CR24", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1016/0092-8674(90)90801-K", "volume": "61", "author": "A. Ullrich", "year": "1990", "unstructured": "A. Ullrich and J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity, Cell 61:203 (1990).", "journal-title": "Cell"}, {"key": "28_CR25", "doi-asserted-by": "crossref", "first-page": "4770", "DOI": "10.1128/MCB.10.9.4770", "volume": "10", "author": "W.H. Burgess", "year": "1990", "unstructured": "W.H. Burgess, C.A. Dionne, J. Kaplow, R. Mudd, R. Friesel, A. Zilberstein, J. Schlessinger and M. Jaye, Characterization and cDNA cloning of phospholipase C-y, a major substrate for heparin-binding growth factor-1 (acidic fibroblast growth factor)-activated tyrosine kinase, Mol. Cell. Biol. 10:4770 (1990).", "journal-title": "Mol. Cell. Biol."}, {"key": "28_CR26", "unstructured": "F. Bellot and M. Jaye (manuscript in preparation)."}, {"key": "28_CR27", "first-page": "1187", "volume": "261", "author": "I. Magnaldo", "year": "1986", "unstructured": "I. Magnaldo, G. L\u2019Allemain, J.C. Chambard, M. Moenner, D. Barritault and J. Pouyssegur, The mitogenic signaling pathway of fibroblast growth factor is not mediated through polyphosphoinositide hydrolysis and protein kinase C activation in hamster fibroblasts, J. Biol. Chem. 261:1187 (1986).", "journal-title": "J. Biol. Chem."}, {"key": "28_CR28", "first-page": "1187", "volume": "261", "author": "K. Kaibuchi", "year": "1986", "unstructured": "K. Kaibuchi, T. Tsuda, A. Kikuchi, T. Tanimoto, T. Yamashita and Y. Takai, Possible involvement of protein kinase C and calcium ion in growth factor-induced expression of c-myc oncogene in Swiss 3T3 fibroblasts, J. Biol. Chem. 261:1187 (1986).", "journal-title": "J. Biol. Chem."}, {"key": "28_CR29", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1016/0014-5793(85)80009-0", "volume": "191", "author": "T. Tsuda", "year": "1985", "unstructured": "T. Tsuda, K. Kaibuchi, Y. Kawahara, H. Fukuzaki and Y. Takai, Induction of protein kinase C activation and Ca2+ mobilization by fibroblast growth factor in Swiss 3T3 cells, FEBS Lett. 191:205 (1985).", "journal-title": "FEBS Lett"}, {"key": "28_CR30", "author": "M. Mohammadi", "year": "1992", "unstructured": "M. Mohammadi, C.A. Dionne, W. Li, N. Li, T. Spivak, A.M. Honegger, M. Jaye and J. Schlessinger, A point mutation at tyr 766 of FGF receptor eliminates FGF induced tyrosine phosphorylation of PLC\u03b3 and phosphotidylinositol hydrolysis without affecting mitogenesis, Nature (in press 1992).", "volume-title": "A point mutation at tyr 766 of FGF receptor eliminates FGF induced tyrosine phosphorylation of PLC\u03b3 and phosphotidylinositol hydrolysis without affecting mitogenesis"}, {"key": "28_CR31", "doi-asserted-by": "publisher", "first-page": "603", "DOI": "10.1016/0092-8674(83)90092-2", "volume": "35", "author": "K. Kelly", "year": "1983", "unstructured": "K. Kelly, B.H. Cochran, C.D. Stiles and P. Leder, Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor, Cell 35:603 (1983).", "journal-title": "Cell"}, {"key": "28_CR32", "doi-asserted-by": "publisher", "first-page": "8464", "DOI": "10.1073/pnas.85.22.8464", "volume": "85", "author": "K. Ryder", "year": "1988", "unstructured": "K. Ryder and D. Nathans, Induction of protooncogene c-jun by serum growth factors, Proc. Natl. Acad. Sci. USA 85:8464 (1988).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "28_CR33", "first-page": "3284", "volume": "265", "author": "C.G. Gay", "year": "1990", "unstructured": "C.G. Gay and J.A. Winkles, Heparin-binding growth factor-1 stimulation of human endothelial cells induces platelet-derived growth factor A-chain expression, J. Biol. Chem. 265:3284 (1990).", "journal-title": "J. Biol. Chem."}, {"key": "28_CR34", "doi-asserted-by": "publisher", "first-page": "312", "DOI": "10.1002/jcp.1041360214", "volume": "136", "author": "S.M. Rybak", "year": "1988", "unstructured": "S.M. Rybak, R.R. Lobb and J.W. Fett, Comparison of the effects of class 1 and class 2 heparin-binding growth factors on protein synthesis and actin mRNA expression in Balb/c-3T3 cells, J. Cell. Physiol. 136:312 (1988).", "journal-title": "J. Cell. Physiol."}, {"key": "28_CR35", "doi-asserted-by": "publisher", "first-page": "6770", "DOI": "10.1073/pnas.84.19.6770", "volume": "84", "author": "G. Bouche", "year": "1987", "unstructured": "G. Bouche, N. Gas, H. Prats, V. Baldin, J.-P. Tauber, J. Tessi\u00e9 and F. Amalric, Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing Go\u2014>G transition, Proc. Natl. Acad. Sci. USA 84:6770 (1987).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "28_CR36", "doi-asserted-by": "publisher", "first-page": "2129", "DOI": "10.1083/jcb.111.5.2129", "volume": "111", "author": "W.H. Burgess", "year": "1990", "unstructured": "W.H. Burgess, A.M. Shaheen, M. Rayera, M. Jaye, P.J. Donohue and J.A. Winkles, Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue, J. Cell Biol. 111:2129 (1990).", "journal-title": "J. Cell Biol."}, {"key": "28_CR37", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.1002/jcb.240450203", "volume": "45", "author": "W.H. Burgess", "year": "1991", "unstructured": "W.H. Burgess, A.M. Shaheen, B. Hampton, P.J. Donohue and J.A. Winkles, Structure-function studies of heparin-binding (acidic fibroblast) growth factor-1 using site-directed mutagenesis, J. Cell. Biochem. 45:131 (1991).", "journal-title": "J. Cell. Biochem."}, {"key": "28_CR38", "doi-asserted-by": "publisher", "first-page": "1567", "DOI": "10.1126/science.1699274", "volume": "249", "author": "T. Imamura", "year": "1990", "unstructured": "T. Imamura, K. Engleka, Zhan, Y. Tokita, R. Forough, D. Roeder, A. Jackson, J.A.M. Maier, T. Hla and T. Maciag, Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence, Science 249:1567 (1990).", "journal-title": "Science"}, {"key": "28_CR39", "first-page": "16612", "volume": "262", "author": "M. Jaye", "year": "1987", "unstructured": "M. Jaye, W.H. Burgess, A.B. Shaw and W.N. Drohan, Biological equivalence of natural bovine and recombinant human a-endothelial cell growth factor, J. Biol. Chem. 262:16612 (1987).", "journal-title": "J. Biol. Chem."}, {"key": "28_CR40", "doi-asserted-by": "publisher", "first-page": "159", "DOI": "10.1016/0003-2697(90)90545-K", "volume": "188", "author": "T. Mehlman", "year": "1990", "unstructured": "T. Mehlman and W.H. Burgess, Identification and characterization of heparin-binding proteins using a gel overlay procedure, Anal. Biochem. 188:159 (1990).", "journal-title": "Anal. Biochem."}, {"key": "28_CR41", "doi-asserted-by": "publisher", "first-page": "2324", "DOI": "10.1073/pnas.85.7.2324", "volume": "85", "author": "A Baird", "year": "1988", "unstructured": "A Baird, D. Schubert, N. Ling and R. Guillemin, Receptor and heparin-binding domains of basic fibroblast growth factor, Proc. Natl. Acad. Sci. USA 85:2324 (1988).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "28_CR42", "doi-asserted-by": "crossref", "first-page": "240", "DOI": "10.1128/MCB.12.1.240", "volume": "12", "author": "D.M. Ornitz", "year": "1992", "unstructured": "D.M. Ornitz, A. Yayon, J.G. Flanagan, C.M. Svahn, E. Levi and P. Leder, Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells, Mol. Cell. Biol. 12:240 (1992).", "journal-title": "Mol. Cell. Biol."}, {"key": "28_CR43", "doi-asserted-by": "crossref", "first-page": "2487", "DOI": "10.1128/MCB.9.6.2487", "volume": "9", "author": "D. Chesky", "year": "1989", "unstructured": "D. Chesky, R. Ralph and G. Jonak, Sequence requirements for synthetic peptide-mediated translocation to the nucleus, Mol. Cell. Biol. 9:2487 (1989).", "journal-title": "Mol. Cell. Biol."}, {"key": "28_CR44", "doi-asserted-by": "publisher", "first-page": "671", "DOI": "10.1021/bi00402a027", "volume": "27", "author": "J.W. Harper", "year": "1988", "unstructured": "J.W. Harper and R.R. Lobb, Reductive methylation of lysine residues in acidic fibroblast growth factor: effect on mitogenic activity and heparin affinity, Biochemistry 27:671 (1988).", "journal-title": "Biochemistry"}, {"key": "28_CR45", "doi-asserted-by": "publisher", "first-page": "841", "DOI": "10.1016/0092-8674(91)90512-W", "volume": "64", "author": "A. Yayon", "year": "1991", "unstructured": "A. Yayon, M. Klagsbrun, J.D. Esko, P. Leder and D.M. Ornitz, Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high-affinity receptor, Cell 64:841 (1991).", "journal-title": "Cell"}, {"key": "28_CR46", "doi-asserted-by": "publisher", "first-page": "631", "DOI": "10.1083/jcb.118.3.631", "volume": "118", "author": "B.B. Olwin", "year": "1992", "unstructured": "B.B. Olwin and A. Rapraeger, Repression of myogenic differentiation by aFGF, bFGF and K-FGF is dependent on cellular heparan sulfate, J. Cell Biol. 118:631 (1992).", "journal-title": "J. Cell Biol."}, {"key": "28_CR47", "unstructured": "A.M. Shaheen and W.H. Burgess (manuscript in preparation)."}, {"key": "28_CR48", "first-page": "79", "volume": "106", "author": "G.D. Paterno", "year": "1989", "unstructured": "G.D. Paterno, L.L. Gillepsie, M.S. Dixon, J.M.W. Slack and J.K. Heath, Mesoderm-inducing properties of INT-2 and kFGF: two oncogene-encoded growth factors related to FGF, Development 106:79 (1989).", "journal-title": "Development"}, {"key": "28_CR49", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1016/0092-8674(91)90616-7", "volume": "66", "author": "E. Amaya", "year": "1991", "unstructured": "E. Amaya, T.J. Music and M.W. Kirschner, Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos, Cell 66:257 (1991).", "journal-title": "Cell"}, {"key": "28_CR50", "doi-asserted-by": "publisher", "first-page": "411", "DOI": "10.1016/0092-8674(89)90026-3", "volume": "59", "author": "M.J. Berridge", "year": "1989", "unstructured": "M.J. Berridge, C.R. Downes and M.J. Hanley, Neural and developmental actions of lithium: a unifying hypothesis, Cell 59:411 (1989).", "journal-title": "Cell"}, {"key": "28_CR51", "unstructured": "R.F. Friesel and W.H. Burgess (manuscript in preparation)."}, {"key": "28_CR52", "doi-asserted-by": "publisher", "first-page": "1623", "DOI": "10.1083/jcb.101.4.1623", "volume": "101", "author": "A.B. Schreiber", "year": "1985", "unstructured": "A.B. Schreiber, J. Kenney, J. Kowalski, K.A. Thomas, G. Gimenez-Gallego, M. Rios-Candelore, J. DiSalvo, D. Barritault, J. Courty, Y. Courtois, M. Moenner, C. Loret, W.H. Burgess, T. Mehlman, R. Friesel, W. Johnson and T. Maciag, A unique family of endothelial cell polypeptide mitogens: the antigenic and receptor cross-reactivity of bovine endothelial cell growth factor, brain-derived acidic fibroblast growth factor, and eye-derived growth factor-II, J. Cell Biol. 101:1623 (1985).", "journal-title": "J. Cell Biol."}, {"key": "28_CR53", "first-page": "5842", "volume": "266", "author": "S. Ortega", "year": "1991", "unstructured": "S. Ortega, M.-T. Schaeffer, D. Soderman, J. DiSalvo, D.L. Linemeyer, G. Gimenez-Gallego and K.A. Thomas, Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor, J. Biol. Chem. 266:5842 (1991).", "journal-title": "J. Biol. Chem."}], "container-title": ["Growth Factors, Peptides and Receptors"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4615-2846-3_28", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 30]], "date-time": "2019-03-30T20:14:53Z", "timestamp": 1553976893000}, "score": 22.537483, "issued": {"date-parts": [[1993]]}, "ISBN": ["9780306444845", "9781461528463"], "references-count": 53, "URL": "http://dx.doi.org/10.1007/978-1-4615-2846-3_28", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T15:11:39Z", "timestamp": 1575299499177}, "publisher-location": "Weinheim, Germany", "reference-count": 102, "publisher": "Wiley-VCH Verlag GmbH & Co. KGaA", "isbn-type": [{"value": "9783527333059", "type": "print"}, {"value": "9783527659685", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9783527659685.ch20", "type": "book-chapter", "created": {"date-parts": [[2013, 10, 25]], "date-time": "2013-10-25T15:14:06Z", "timestamp": 1382714046000}, "page": "471-490", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Peptidyltransferase Inhibitors of the Bacterial Ribosome"], "prefix": "10.1002", "author": [{"given": "Daniel", "family": "Wilson", "sequence": "first", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2013, 10, 4]]}, "reference": [{"key": "10.1002/9783527659685.ch20-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "612", "DOI": "10.1016/j.bbagrm.2009.06.006", "article-title": "A structural view on the mechanism of the ribosome-catalyzed peptide bond formation", "volume": "1789", "author": "Simonovic", "year": "2009", "journal-title": "Biochim. Biophys. Acta"}, {"key": "10.1002/9783527659685.ch20-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "285", "DOI": "10.1080/10409230500326334", "article-title": "The ribosomal peptidyl transferase center: structure, function, evolution, inhibition", "volume": "40", "author": "Polacek", "year": "2005", "journal-title": "Crit. Rev. Biochem. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "878", "DOI": "10.1126/science.289.5481.878", "article-title": "Structural biology. The ribosome is a ribozyme", "volume": "289", "author": "Cech", "year": "2000", "journal-title": "Science"}, {"key": "10.1002/9783527659685.ch20-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "814", "DOI": "10.1038/35101544", "article-title": "Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria", "volume": "413", "author": "Schl\u00fcnzen", "year": "2001", "journal-title": "Nature"}, {"key": "10.1002/9783527659685.ch20-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1061", "DOI": "10.1016/S0022-2836(03)00668-5", "article-title": "Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit", "volume": "330", "author": "Hansen", "year": "2003", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "17152", "DOI": "10.1073/pnas.1007988107", "article-title": "Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action", "volume": "107", "author": "Dunkle", "year": "2010", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "17158", "DOI": "10.1073/pnas.1008685107", "article-title": "Revisiting the structures of several antibiotics bound to the bacterial ribosome", "volume": "107", "author": "Bulkley", "year": "2010", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1016/j.cell.2005.02.005", "article-title": "Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance", "volume": "121", "author": "Tu", "year": "2005", "journal-title": "Cell"}, {"key": "10.1002/9783527659685.ch20-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.1016/j.jmb.2008.03.075", "article-title": "Mutations outside the anisomycin-binding site can make ribosomes drug-resistant", "volume": "379", "author": "Blaha", "year": "2008", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1016/S1097-2765(03)00009-1", "article-title": "Structural basis of the ribosomal machinery for peptide bond formation, translocation, and nascent chain progression", "volume": "11", "author": "Bashan", "year": "2003", "journal-title": "Mol. Cell"}, {"key": "10.1002/9783527659685.ch20-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "920", "DOI": "10.1126/science.289.5481.920", "article-title": "The structural basis of ribosome activity in peptide bond synthesis", "volume": "289", "author": "Nissen", "year": "2000", "journal-title": "Science"}, {"key": "10.1002/9783527659685.ch20-BIB12|cit12", "first-page": "225", "article-title": "A pre-translocational intermediate in protein synthesis observed in crystals of enzymatically active 50S subunits", "volume": "9", "author": "Schmeing", "year": "2002", "journal-title": "Nat. Struct. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "11670", "DOI": "10.1073/pnas.172404099", "article-title": "Structural insights into peptide bond formation", "volume": "99", "author": "Hansen", "year": "2002", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "3353", "DOI": "10.1021/jm800379d", "article-title": "Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit", "volume": "51", "author": "Ippolito", "year": "2008", "journal-title": "J. Med. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "13339", "DOI": "10.1073/pnas.0804276105", "article-title": "The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning", "volume": "105", "author": "Wilson", "year": "2008", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "4291", "DOI": "10.1073/pnas.0700041104", "article-title": "Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity", "volume": "104", "author": "Davidovich", "year": "2007", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "1287", "DOI": "10.1111/j.1365-2958.2004.04346.x", "article-title": "Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin", "volume": "54", "author": "Schluenzen", "year": "2004", "journal-title": "Mol. Microbiol."}, {"key": "10.1002/9783527659685.ch20-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "146", "DOI": "10.1016/j.jmb.2009.04.005", "article-title": "U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome", "volume": "389", "author": "Gurel", "year": "2009", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "4", "DOI": "10.1186/1741-7007-2-4", "article-title": "Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin", "volume": "2", "author": "Harms", "year": "2004", "journal-title": "BMC Biol."}, {"key": "10.1002/9783527659685.ch20-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1016/j.molcel.2005.09.006", "article-title": "Structural insights into the roles of water and the 2\u2032 hydroxyl of the P site tRNA in the peptidyl transferase reaction", "volume": "20", "author": "Schmeing", "year": "2005", "journal-title": "Mol. Cell"}, {"key": "10.1002/9783527659685.ch20-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "520", "DOI": "10.1038/nature04152", "article-title": "An induced-fit mechanism to promote peptide bond formation and exclude hydrolysis of peptidyl-tRNA", "volume": "438", "author": "Schmeing", "year": "2005", "journal-title": "Nature"}, {"key": "10.1002/9783527659685.ch20-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "242", "DOI": "10.1038/nrm2352", "article-title": "A structural understanding of the dynamic ribosome machine", "volume": "9", "author": "Steitz", "year": "2008", "journal-title": "Nat. Rev. Mol. Cell Biol."}, {"key": "10.1002/9783527659685.ch20-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "393", "DOI": "10.1016/j.molcel.2007.04.005", "article-title": "The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria", "volume": "26", "author": "Leach", "year": "2007", "journal-title": "Mol. Cell"}, {"key": "10.1002/9783527659685.ch20-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "393", "DOI": "10.3109/10409230903307311", "article-title": "The A-Z of bacterial translation inhibitors", "volume": "44", "author": "Wilson", "year": "2009", "journal-title": "Crit. Rev. Biochem. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "247", "DOI": "10.1016/0014-5793(71)80546-X", "article-title": "Substrate and antibiotic binding sites at the peptidyl transferase centre of E. coli ribosomes: binding of UACCA-Leu to 50S subunits", "volume": "13", "author": "Celma", "year": "1971", "journal-title": "FEBS Lett."}, {"key": "10.1002/9783527659685.ch20-BIB26|cit26", "first-page": "6909", "article-title": "Studies on the formation of transfer ribonucleic acid-ribosome complexes. 23. Chloramphenicol, aminoacyl-oligonucleotides, and Escherichia coli ribosomes", "volume": "247", "author": "Lessard", "year": "1972", "journal-title": "J. Biol. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "7208", "DOI": "10.1093/nar/gkg945", "article-title": "A conserved chloramphenicol binding site at the entrance to the ribosomal peptide exit tunnel", "volume": "31", "author": "Long", "year": "2003", "journal-title": "Nucleic Acids Res."}, {"key": "10.1002/9783527659685.ch20-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "1064", "DOI": "10.1111/j.1365-2958.2005.04754.x", "article-title": "A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503", "volume": "57", "author": "Kehrenberg", "year": "2005", "journal-title": "Mol. Microbiol."}, {"key": "10.1002/9783527659685.ch20-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "589", "DOI": "10.1016/0006-291X(69)90345-3", "article-title": "Studies on the formation of transfer ribonucleic acid-ribosome complexes. X. Phenylalanyl-oligonucleotide binding to ribosomes and the mechanism of chloramphenicol action", "volume": "36", "author": "Pestka", "year": "1969", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "10.1002/9783527659685.ch20-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1073/pnas.64.2.709", "article-title": "Studies on the formation of transfer ribonucleic acid-ribosome complexes. XI. Antibiotic effects on phenylalanyl-oligonucleotide binding to ribosomes", "volume": "64", "author": "Pestka", "year": "1969", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "643", "DOI": "10.1111/j.1432-1033.1990.tb19382.x", "article-title": "Partial release of AcPhe-Phe-transfer RNA from ribosomes during Poly(U)-dependent Poly(Phe) synthesis and the effects of chloramphenicol", "volume": "193", "author": "Rheinberger", "year": "1990", "journal-title": "Eur. J. Biochem."}, {"key": "10.1002/9783527659685.ch20-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1016/S0022-2836(02)00784-2", "article-title": "The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo", "volume": "322", "author": "Thompson", "year": "2002", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "4889", "DOI": "10.1128/AAC.48.12.4889-4891.2004", "article-title": "Effects of a number of classes of 50S inhibitors on stop codon readthrough during protein synthesis", "volume": "48", "author": "Thompson", "year": "2004", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "49", "DOI": "10.1111/j.1749-6632.2011.05962.x", "article-title": "Linezolid, the first oxazolidinone antibacterial agent", "volume": "1222", "author": "Leach", "year": "2011", "journal-title": "Ann. N.Y. Acad. Sci."}, {"key": "10.1002/9783527659685.ch20-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.1006/jmbi.1999.3247", "article-title": "Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center", "volume": "294", "author": "Kloss", "year": "1999", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "2154", "DOI": "10.1128/AAC.45.7.2154-2156.2001", "article-title": "Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci", "volume": "45", "author": "Prystowsky", "year": "2001", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB37|cit37", "author": "Wilson", "first-page": "449", "year": "2004", "volume-title": "Protein Synthesis and Ribosome Structure"}, {"key": "10.1002/9783527659685.ch20-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "2127", "DOI": "10.1128/AAC.41.10.2127", "article-title": "The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin", "volume": "41", "author": "Lin", "year": "1997", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "3550", "DOI": "10.1128/AAC.01193-07", "article-title": "R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance", "volume": "52", "author": "Skripkin", "year": "2008", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "965", "DOI": "10.1016/0006-291X(88)90723-1", "article-title": "The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis", "volume": "150", "author": "Eustice", "year": "1988", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "10.1002/9783527659685.ch20-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "2132", "DOI": "10.1128/AAC.41.10.2132", "article-title": "Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions", "volume": "41", "author": "Shinabarger", "year": "1997", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "21972", "DOI": "10.1074/jbc.M302109200", "article-title": "Crosslinking in the living cell locates the site of action of oxazolidinone antibiotics", "volume": "278", "author": "Colca", "year": "2003", "journal-title": "J. Biol. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB43|cit43", "doi-asserted-by": "crossref", "first-page": "721", "DOI": "10.1016/j.cell.2006.09.037", "article-title": "The highly conserved LepA is a ribosomal elongation factor that back-translocates the ribosome", "volume": "127", "author": "Qin", "year": "2006", "journal-title": "Cell"}, {"key": "10.1002/9783527659685.ch20-BIB44|cit44", "doi-asserted-by": "crossref", "first-page": "1043", "DOI": "10.1016/j.jmb.2009.12.043", "article-title": "Interrupted catalysis: the EF4 (LepA) effect on back-translocation", "volume": "396", "author": "Liu", "year": "2010", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB45|cit45", "doi-asserted-by": "crossref", "first-page": "910", "DOI": "10.1038/nsmb.1469", "article-title": "A new tRNA intermediate revealed on the ribosome during EF4-mediated back-translocation", "volume": "15", "author": "Connell", "year": "2008", "journal-title": "Nat. Struct. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB46|cit46", "doi-asserted-by": "crossref", "first-page": "16223", "DOI": "10.1073/pnas.1103820108", "article-title": "The conserved protein EF4 (LepA) modulates the elongation cycle of protein synthesis", "volume": "108", "author": "Liu", "year": "2011", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1016/j.biochi.2009.11.002", "article-title": "Translation factor LepA contributes to tellurite resistance in Escherichia coli but plays no apparent role in the fidelity of protein synthesis", "volume": "92", "author": "Shoji", "year": "2010", "journal-title": "Biochimie"}, {"key": "10.1002/9783527659685.ch20-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "3199", "DOI": "10.1073/pnas.1012994108", "article-title": "Elongation factor 4 (EF4/LepA) accelerates protein synthesis at increased Mg2+ concentrations", "volume": "108", "author": "Pech", "year": "2011", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB49|cit49", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1016/S0065-2164(04)56004-5", "article-title": "Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications", "volume": "56", "author": "Spizek", "year": "2004", "journal-title": "Adv. Appl. Microbiol."}, {"key": "10.1002/9783527659685.ch20-BIB50|cit50", "doi-asserted-by": "crossref", "first-page": "1042", "DOI": "10.1124/mol.56.5.1042", "article-title": "Slow sequential conformational changes in Escherichia coli ribosomes induced by lincomycin: kinetic evidence", "volume": "56", "author": "Kallia-Raftopoulos", "year": "1999", "journal-title": "Mol. Pharmacol."}, {"key": "10.1002/9783527659685.ch20-BIB51|cit51", "author": "Gale", "first-page": "278", "year": "1981", "volume-title": "The Molecular Basis of Antibiotic Action"}, {"key": "10.1002/9783527659685.ch20-BIB52|cit52", "first-page": "140", "article-title": "Macrolide antibiotic interaction and resistance on the bacterial ribosome", "volume": "4", "author": "Poehlsgaard", "year": "2003", "journal-title": "Curr. Opin. Invest. Drugs"}, {"key": "10.1002/9783527659685.ch20-BIB53|cit53", "doi-asserted-by": "crossref", "first-page": "1553", "DOI": "10.1128/AAC.49.4.1553-1555.2005", "article-title": "Molecular mechanisms by which rRNA mutations confer resistance to clindamycin", "volume": "49", "author": "Poehlsgaard", "year": "2005", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB54|cit54", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1016/0014-5793(70)80076-X", "article-title": "Substrate and antibiotic binding sites at the peptidyl transferase centre of E. coli ribosomes", "volume": "6", "author": "Celma", "year": "1970", "journal-title": "FEBS Lett."}, {"key": "10.1002/9783527659685.ch20-BIB55|cit55", "first-page": "1", "article-title": "Blasticidin S, a new antibiotic", "volume": "11", "author": "Takeuchi", "year": "1958", "journal-title": "J. Antibiot."}, {"key": "10.1002/9783527659685.ch20-BIB56|cit56", "doi-asserted-by": "crossref", "first-page": "224", "DOI": "10.1006/jmbi.1994.0135", "article-title": "Fine structure of the peptidyl transferase centre on 23 S-like rRNAs deduced from chemical probing of antibiotic-ribosome complexes", "volume": "247", "author": "Rodriguez-Fonseca", "year": "1995", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB57|cit57", "author": "Suhadolnik", "year": "1970", "volume-title": "Nucleoside Antibiotics"}, {"key": "10.1002/9783527659685.ch20-BIB58|cit58", "author": "Vasquez", "year": "1979", "volume-title": "Inhibitors of Protein Synthesis", "DOI": "10.1007/978-3-642-81309-2", "doi-asserted-by": "crossref"}, {"key": "10.1002/9783527659685.ch20-BIB59|cit59", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1016/0014-5793(74)80062-1", "article-title": "Structural basis for inhibition of protein synthesis by the aminoacyl-aminohexosyl-cytosine group of antibiotics", "volume": "38", "author": "Lichtenthaler", "year": "1974", "journal-title": "FEBS Lett."}, {"key": "10.1002/9783527659685.ch20-BIB60|cit60", "doi-asserted-by": "crossref", "first-page": "877", "DOI": "10.1139/o95-095", "article-title": "Antibiotic inhibition of the movement of tRNA substrates through a peptidyl transferase cavity", "volume": "73", "author": "Porse", "year": "1995", "journal-title": "Biochem. Cell Biol."}, {"key": "10.1002/9783527659685.ch20-BIB61|cit61", "doi-asserted-by": "crossref", "first-page": "26518", "DOI": "10.1074/jbc.M313634200", "article-title": "Polyamines affect diversely the antibiotic potency: insight gained from kinetic studies of the blasticidin S and spiramycin interactions with functional ribosomes", "volume": "279", "author": "Petropoulos", "year": "2004", "journal-title": "J. Biol. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB62|cit62", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1128/AAC.35.1.10", "article-title": "Interaction of the antibiotic sparsomycin with the ribosome", "volume": "35", "author": "Lazaro", "year": "1991", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB63|cit63", "doi-asserted-by": "crossref", "first-page": "222", "DOI": "10.1006/jmbi.1996.0454", "article-title": "Mutations in the peptidyl transferase center of 23 S rRNA reveal the site of action of sparsomycin, a universal inhibitor of translation", "volume": "261", "author": "Tan", "year": "1996", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB64|cit64", "doi-asserted-by": "crossref", "first-page": "231", "DOI": "10.1006/jmbi.1996.0455", "article-title": "A sparsomycin-resistant mutant of Halobacterium salinarium lacks a modification at nucleotide U2603 in the peptidyl transferase centre of 23 S rRNA", "volume": "261", "author": "Lazaro", "year": "1996", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB65|cit65", "doi-asserted-by": "crossref", "first-page": "9003", "DOI": "10.1073/pnas.96.16.9003", "article-title": "Direct crosslinking of the antitumor antibiotic sparsomycin, and its derivatives, to A2602 in the peptidyl transferase center of 23S-like rRNA within ribosome-tRNA complexes", "volume": "96", "author": "Porse", "year": "1999", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB66|cit66", "doi-asserted-by": "crossref", "first-page": "9642", "DOI": "10.1021/bi00104a011", "article-title": "Biochemical and kinetic characteristics of the interaction of the antitumor antibiotic sparsomycin with prokaryotic and eukaryotic ribosomes", "volume": "30", "author": "Lazaro", "year": "1991", "journal-title": "Biochemistry"}, {"key": "10.1002/9783527659685.ch20-BIB67|cit67", "doi-asserted-by": "crossref", "first-page": "1159", "DOI": "10.1126/science.1084571", "article-title": "Catalysis of ribosomal translocation by sparsomycin", "volume": "300", "author": "Fredrick", "year": "2003", "journal-title": "Science"}, {"key": "10.1002/9783527659685.ch20-BIB68|cit68", "doi-asserted-by": "crossref", "first-page": "2543", "DOI": "10.1046/j.1432-1033.2003.03634.x", "article-title": "On peptide bond formation, translocation, nascent protein progression and the regulatory properties of ribosomes", "volume": "270", "author": "Agmon", "year": "2003", "journal-title": "Eur. J. Biochem."}, {"key": "10.1002/9783527659685.ch20-BIB69|cit69", "doi-asserted-by": "crossref", "first-page": "115", "DOI": "10.1006/abio.1997.2034", "article-title": "Determination of eukaryotic peptidyltransferase activity by pseudo-first-order kinetic analysis", "volume": "247", "author": "Ioannou", "year": "1997", "journal-title": "Anal. Biochem."}, {"key": "10.1002/9783527659685.ch20-BIB70|cit70", "first-page": "182", "article-title": "The pleuromutilin antibiotics: a new class for human use", "volume": "11", "author": "Novak", "year": "2010", "journal-title": "Curr. Opin. Invest. Drugs"}, {"key": "10.1002/9783527659685.ch20-BIB71|cit71", "doi-asserted-by": "crossref", "first-page": "923", "DOI": "10.7164/antibiotics.29.923", "article-title": "New pleuromutilin derivatives with enhanced antimicrobial activity. II. Structure-activity correlations", "volume": "29", "author": "Egger", "year": "1976", "journal-title": "J. Antibiot."}, {"key": "10.1002/9783527659685.ch20-BIB72|cit72", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1358/dot.2008.44.2.1153446", "article-title": "Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections", "volume": "44", "author": "Parish", "year": "2008", "journal-title": "Drugs Today (Barc.)"}, {"key": "10.1002/9783527659685.ch20-BIB73|cit73", "doi-asserted-by": "crossref", "first-page": "527", "DOI": "10.1111/j.1432-1033.1974.tb03721.x", "article-title": "The mode of action of pleuromutilin derivatives. Effect on cell-free polypeptide synthesis", "volume": "47", "author": "Hodgin", "year": "1974", "journal-title": "Eur. J. Biochem."}, {"key": "10.1002/9783527659685.ch20-BIB74|cit74", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.1111/j.1432-1033.1975.tb03976.x", "article-title": "The mode of action of pleuromutilin derivatives. Location and properties of the pleuromutilin binding site on Escherichia coli ribosomes", "volume": "52", "author": "Hogenauer", "year": "1975", "journal-title": "Eur. J. Biochem."}, {"key": "10.1002/9783527659685.ch20-BIB75|cit75", "doi-asserted-by": "crossref", "first-page": "4957", "DOI": "10.1021/jm800261u", "article-title": "A click chemistry approach to pleuromutilin conjugates with nucleosides or acyclic nucleoside derivatives and their binding to the bacterial ribosome", "volume": "51", "author": "Lolk", "year": "2008", "journal-title": "J. Med. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB76|cit76", "doi-asserted-by": "crossref", "first-page": "1458", "DOI": "10.1128/AAC.50.4.1458-1462.2006", "article-title": "Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center", "volume": "50", "author": "Long", "year": "2006", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB77|cit77", "doi-asserted-by": "crossref", "first-page": "1295", "DOI": "10.1111/j.1365-2958.2004.04373.x", "article-title": "Mutations in ribosomal protein L3 and 23S ribosomal RNA at the peptidyl transferase centre are associated with reduced susceptibility to tiamulin in Brachyspira spp. isolates", "volume": "54", "author": "Pringle", "year": "2004", "journal-title": "Mol. Microbiol."}, {"key": "10.1002/9783527659685.ch20-BIB78|cit78", "doi-asserted-by": "crossref", "first-page": "1737", "DOI": "10.1128/AAC.01015-07", "article-title": "Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center", "volume": "52", "author": "Miller", "year": "2008", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB79|cit79", "doi-asserted-by": "crossref", "first-page": "1218", "DOI": "10.1111/j.1365-2958.2009.06596.x", "article-title": "Single 23S rRNA mutations at the ribosomal peptidyl transferase centre confer resistance to valnemulin and other antibiotics in Mycobacterium smegmatis by perturbation of the drug binding pocket", "volume": "71", "author": "Long", "year": "2009", "journal-title": "Mol. Microbiol."}, {"key": "10.1002/9783527659685.ch20-BIB80|cit80", "doi-asserted-by": "crossref", "first-page": "20665", "DOI": "10.1073/pnas.0810826105", "article-title": "Structural basis for cross-resistance to ribosomal PTC antibiotics", "volume": "105", "author": "Davidovich", "year": "2008", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB81|cit81", "doi-asserted-by": "crossref", "first-page": "2892", "DOI": "10.1128/AAC.47.9.2892-2896.2003", "article-title": "Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein L3", "volume": "47", "author": "Bosling", "year": "2003", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB82|cit82", "doi-asserted-by": "crossref", "first-page": "465", "DOI": "10.1111/j.1432-1033.1978.tb12699.x", "article-title": "The effects of tiamulin, a semisynthetic pleuromutilin derivative, on bacterial polypeptide chain initiation", "volume": "91", "author": "Dornhelm", "year": "1978", "journal-title": "Eur. J. Biochem."}, {"issue": "Suppl. A", "key": "10.1002/9783527659685.ch20-BIB83|cit83", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1093/jac/39.suppl_1.7", "article-title": "Inhibition of protein synthesis by streptogramins and related antibiotics", "volume": "39", "author": "Cocito", "year": "1997", "journal-title": "J. Antimicrob. Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB84|cit84", "doi-asserted-by": "crossref", "first-page": "529", "DOI": "10.1021/cr030110z", "article-title": "Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis", "volume": "105", "author": "Mukhtar", "year": "2005", "journal-title": "Chem. Rev."}, {"key": "10.1002/9783527659685.ch20-BIB85|cit85", "doi-asserted-by": "crossref", "first-page": "1061", "DOI": "10.2165/00003495-199958060-00008", "article-title": "Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections", "volume": "58", "author": "Lamb", "year": "1999", "journal-title": "Drugs"}, {"key": "10.1002/9783527659685.ch20-BIB86|cit86", "first-page": "9563", "article-title": "The action of virginiamycin M on the acceptor, donor, and catalytic sites of peptidyltransferase", "volume": "259", "author": "Chinali", "year": "1984", "journal-title": "J. Biol. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB87|cit87", "doi-asserted-by": "crossref", "first-page": "485", "DOI": "10.1093/jac/24.4.485", "article-title": "The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes", "volume": "24", "author": "Di Giambattista", "year": "1989", "journal-title": "J. Antimicrob. Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB88|cit88", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.1016/0167-4781(89)90076-6", "article-title": "Analysis of the reversible binding of virginiamycin M to ribosome and particle functions after removal of the antibiotic", "volume": "1009", "author": "Nyssen", "year": "1989", "journal-title": "Biochim. Biophys. Acta"}, {"key": "10.1002/9783527659685.ch20-BIB89|cit89", "doi-asserted-by": "crossref", "first-page": "5492", "DOI": "10.1073/pnas.77.9.5492", "article-title": "Lasting damage to bacterial ribosomes by reversibly bound virginiamycin M", "volume": "77", "author": "Parfait", "year": "1980", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "10.1002/9783527659685.ch20-BIB90|cit90", "first-page": "16114", "article-title": "The role of rRNA bases in the interaction of peptidyltransferase inhibitors with bacterial ribosomes", "volume": "267", "author": "Vannuffel", "year": "1992", "journal-title": "J. Biol. Chem."}, {"key": "10.1002/9783527659685.ch20-BIB91|cit91", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1006/jmbi.1998.2509", "article-title": "Sites of interaction of streptogramin A and B antibiotics in the peptidyl transferase loop of 23 S rRNA and the synergism of their inhibitory mechanisms", "volume": "286", "author": "Porse", "year": "1999", "journal-title": "J. Mol. Biol."}, {"key": "10.1002/9783527659685.ch20-BIB92|cit92", "doi-asserted-by": "crossref", "first-page": "42", "DOI": "10.1016/0167-4781(88)90023-1", "article-title": "Action of erythromycin and virginiamycin S on polypeptide synthesis in cell-free systems", "volume": "951", "author": "Chinali", "year": "1988", "journal-title": "Biochim. Biophys. Acta"}, {"key": "10.1002/9783527659685.ch20-BIB93|cit93", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1016/0167-4781(88)90056-5", "article-title": "Inhibition of polypeptide synthesis in cell-free systems by virginiamycin S and erythromycin. Evidence for a common mode of action of type B synergimycins and 14-membered macrolides", "volume": "949", "author": "Chinali", "year": "1988", "journal-title": "Biochim. Biophys. Acta"}, {"key": "10.1002/9783527659685.ch20-BIB94|cit94", "doi-asserted-by": "crossref", "first-page": "236", "DOI": "10.1016/0005-2787(81)90177-5", "article-title": "Competition between erythromycin and virginiamycin for in vitro binding to the large ribosomal subunit", "volume": "654", "author": "Parfait", "year": "1981", "journal-title": "Biochim. Biophys. Acta"}, {"key": "10.1002/9783527659685.ch20-BIB95|cit95", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1093/jac/18.3.307", "article-title": "Antagonistic interactions of macrolides and synergimycins on bacterial ribosomes", "volume": "18", "author": "Di Giambattista", "year": "1986", "journal-title": "J. Antimicrob. Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB96|cit96", "doi-asserted-by": "crossref", "first-page": "879", "DOI": "10.1016/0300-9084(87)90215-X", "article-title": "Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA", "volume": "69", "author": "Moazed", "year": "1987", "journal-title": "Biochimie"}, {"key": "10.1002/9783527659685.ch20-BIB97|cit97", "doi-asserted-by": "crossref", "first-page": "4449", "DOI": "10.1093/nar/22.21.4449", "article-title": "Chemical probing of a virginiamycin M-promoted conformational change of the peptidyl-transferase domain", "volume": "22", "author": "Vannuffel", "year": "1994", "journal-title": "Nucleic Acids Res."}, {"key": "10.1002/9783527659685.ch20-BIB98|cit98", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1007/BF00379728", "article-title": "A spectrofluorimetric study of the interaction between virginiamycin S and bacterial ribosomes", "volume": "166", "author": "Parfait", "year": "1978", "journal-title": "Mol. Gen. Genet."}, {"key": "10.1002/9783527659685.ch20-BIB99|cit99", "doi-asserted-by": "crossref", "first-page": "19", "DOI": "10.2174/1568005013343281", "article-title": "Bacterial ribosomal subunit synthesis: a novel antibiotic target", "volume": "1", "author": "Champney", "year": "2001", "journal-title": "Curr. Drug Targets Infect. Disord."}, {"key": "10.1002/9783527659685.ch20-BIB100|cit100", "doi-asserted-by": "crossref", "first-page": "215", "DOI": "10.2174/1568005014606152", "article-title": "Overcoming bacterial resistance by dual target inhibition: the case of streptogramins", "volume": "1", "author": "Canu", "year": "2001", "journal-title": "Curr. Drug Targets Infect. Disord."}, {"key": "10.1002/9783527659685.ch20-BIB101|cit101", "doi-asserted-by": "crossref", "first-page": "319", "DOI": "10.1128/AAC.45.1.319-323.2001", "article-title": "Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae", "volume": "45", "author": "Depardieu", "year": "2001", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "10.1002/9783527659685.ch20-BIB102|cit102", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1111/j.1749-6632.2011.06192.x", "article-title": "On the specificity of antibiotics targeting the large ribosomal subunit", "volume": "1241", "author": "Wilson", "year": "2011", "journal-title": "Ann. N.Y. Acad. Sci."}], "container-title": ["Antibiotics"], "link": [{"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/9783527659685.ch20", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 31]], "date-time": "2019-07-31T09:39:43Z", "timestamp": 1564565983000}, "score": 22.128006, "issued": {"date-parts": [[2013, 10, 4]]}, "ISBN": ["9783527659685", "9783527333059"], "references-count": 102, "URL": "http://dx.doi.org/10.1002/9783527659685.ch20", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T12:11:10Z", "timestamp": 1574511070142}, "publisher-location": "New York, NY", "reference-count": 109, "publisher": "Springer New York", "isbn-type": [{"value": "9781441984586", "type": "print"}, {"value": "9781441984593", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011]]}, "DOI": "10.1007/978-1-4419-8459-3_11", "type": "book-chapter", "created": {"date-parts": [[2011, 5, 6]], "date-time": "2011-05-06T19:01:43Z", "timestamp": 1304708503000}, "page": "203-219", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL"], "prefix": "10.1007", "author": [{"given": "S.", "family": "Wilson", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2011, 3, 31]]}, "reference": [{"issue": "5600", "key": "11_CR1_11", "doi-asserted-by": "publisher", "first-page": "1912", "DOI": "10.1126/science.1075762", "volume": "298", "author": "G Manning", "year": "2002", "unstructured": "Manning G, Whyte D, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002; 298(5600): 1912\u20131934.", "journal-title": "Science."}, {"key": "11_CR2_11", "doi-asserted-by": "publisher", "first-page": "531", "DOI": "10.1634/theoncologist.8-6-531", "volume": "8", "author": "G Vlahovic", "year": "2003", "unstructured": "Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist. 2003; 8: 531\u2013538.", "journal-title": "Oncologist."}, {"key": "11_CR3_11", "unstructured": "Blume \u2013 Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001; 411: 355\u2013356.", "DOI": "10.1038/35077225", "doi-asserted-by": "crossref"}, {"key": "11_CR4_11", "first-page": "1497", "volume": "132", "author": "P Nowell", "year": "1960", "unstructured": "Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 1960; 132: 1497.", "journal-title": "Science."}, {"issue": "12", "key": "11_CR5_11", "first-page": "1911", "volume": "10", "author": "M Nakao", "year": "1996", "unstructured": "Ross TS, Bernard OA, Berger R, et al. Fusion of huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998; 91(12): 4419\u20134426.", "journal-title": "Leukemia."}, {"issue": "12", "key": "11_CR6_11", "first-page": "1911", "volume": "10", "author": "M Nakao", "year": "1996", "unstructured": "Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996; 10(12): 1911\u20131918.", "journal-title": "Leukemia."}, {"key": "11_CR7_11", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1002/(SICI)1096-9098(199809)69:1<21::AID-JSO5>3.0.CO;2-M", "volume": "69", "author": "S Burow", "year": "1998", "unstructured": "Burow S, Andrulis I, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J. Surg. Oncol. 1998; 69: 21\u201327.", "journal-title": "J. Surg. Oncol."}, {"key": "11_CR8_11", "first-page": "4187", "volume": "57", "author": "BK Rasheed", "year": "1997", "unstructured": "Rasheed BK, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997; 57: 4187\u20134190.", "journal-title": "Cancer Res."}, {"key": "11_CR9_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in Non \u2013 Small Cell Lung Carcinoma. Am Journal Clinical Pathology. 2006; 1256: 860\u2013865.", "journal-title": "J Biol Chem."}, {"key": "11_CR10_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Shinojima N, Tada K, Shirasishi S, et al. Prognostic Value of Epidermal Growth Factor Receptor in Patients with Gliobastoma Multiforme. Cancer Res. 2003; 63: 6962\u20136970.", "journal-title": "J Biol Chem."}, {"key": "11_CR11_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Lee JW, Soung YH, Seo SH, et al. Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal and Breast Carcinomas. Clin Cancer Res. 2006; 12: 57\u201361.", "journal-title": "J Biol Chem."}, {"key": "11_CR12_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "LeFevre G, Glotin AL, Calipel A, et al. Roles of stem cell factor/c-KIT and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem. 2004; 30: 31769\u201331779.", "journal-title": "J Biol Chem."}, {"key": "11_CR13_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Tohda S, Yang GS, Ashman LK, et al. Relationship between c-KIT expression and proliferation in acute myeloblastic leukemia cell lines. J Cell Physiol. 1993; 154: 410\u2013418.", "journal-title": "J Biol Chem."}, {"key": "11_CR14_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Feng S, Wang F, Matsubara A, et al. Fibroblast growth factor receptor 2 limits and \u00adreceptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. 1997; 57: 5369\u20135378.", "journal-title": "J Biol Chem."}, {"key": "11_CR15_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Macdonald D, Reiter A, Cross N. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002; 107: 101\u2013107.", "journal-title": "J Biol Chem."}, {"key": "11_CR16_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol. 2001; 114: 362\u2013364.", "journal-title": "J Biol Chem."}, {"key": "11_CR17_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001; 98: 1752\u20131759.", "journal-title": "J Biol Chem."}, {"key": "11_CR18_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Braoudki M, Karpusas M, Katsibardi K, et al. Frequency of FLT3 mutations in childhood lymphoblastic leukemia. Medical Oncology. 2009; 26: 460\u2013462.", "journal-title": "J Biol Chem."}, {"key": "11_CR19_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Sachdev D, Yee D. Disrupting insulin \u2013 like growth factor signalling as a potetnital cancer therapy. Mol Cancer Ther. 2007; 6: 1\u201312.", "journal-title": "J Biol Chem."}, {"key": "11_CR20_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Werner H, Le Roith D. The role of the insulin \u2013 like growth factor system in human cancer Adv Cancer Res. 1996; 68: 183\u2013223.", "journal-title": "J Biol Chem."}, {"key": "11_CR21_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Zantek ND, Azimi M, Fedoro-Chaiken M, et al. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 1999; 10: 629\u2013638.", "journal-title": "J Biol Chem."}, {"key": "11_CR22_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Santoro M, Rosati R, Grieco M, et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene. 1990; 5: 1595\u20131598.", "journal-title": "J Biol Chem."}, {"key": "11_CR23_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Takahashi M, Buma Y, Taniguchi M. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene. 1991; 6: 297\u2013301.", "journal-title": "J Biol Chem."}, {"key": "11_CR24_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708\u2013710.", "journal-title": "J Biol Chem."}, {"key": "11_CR25_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Fleming TP, Saxena A, Clark WC, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 1992; 52: 4550\u20134553.", "journal-title": "J Biol Chem."}, {"key": "11_CR26_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Smith JS, Wang XY, Qian J, et al. Amplification of the platelet derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol. 2000; 59: 495\u2013503.", "journal-title": "J Biol Chem."}, {"key": "11_CR27_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1999; 77: 307\u2013316.", "journal-title": "J Biol Chem."}, {"key": "11_CR28_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Holland SJ, Powell MJ, Franci C, et al. Multiple Roles for the Receptor Tyrosine Kinase AXL in Tumor Formation. Cancer Res. 2005; 65: 9294\u20139303.", "journal-title": "J Biol Chem."}, {"key": "11_CR29_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Rochlitz C, Lohri A, Bacchi M, et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia. 1999; 13: 1352\u20131358.", "journal-title": "J Biol Chem."}, {"key": "11_CR30_11", "doi-asserted-by": "publisher", "first-page": "35486", "DOI": "10.1074/jbc.M404202200", "volume": "279", "author": "I Behrmann", "year": "2004", "unstructured": "Behrmann I, Smyczek T, Heinrich PC, et al. Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak receptor complex to be equivalent to a receptor tyrosine kinase. J Biol Chem. 2004; 279: 35486\u201335493.", "journal-title": "J Biol Chem."}, {"key": "11_CR31_11", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1016/0092-8674(90)90801-K", "volume": "61", "author": "A Ullrich", "year": "1990", "unstructured": "Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61: 203\u2013212.", "journal-title": "Cell."}, {"key": "11_CR109_11", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1016/0092-8674(90)90801-K", "volume": "61", "author": "A Ullrich", "year": "1990", "unstructured": "Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009; 106(23): 9414\u20139418.", "journal-title": "Cell."}, {"key": "11_CR32_11", "doi-asserted-by": "publisher", "first-page": "1473", "DOI": "10.1038/sj.leu.2401127", "volume": "12", "author": "H Rieder", "year": "1998", "unstructured": "Rieder H, Bonwetsch C, Janssen LA, et al. High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia. Leukemia. 1998; 12: 1473\u20131481.", "journal-title": "Leukemia."}, {"key": "11_CR33_11", "first-page": "196", "volume": "5", "author": "LM Secker-Walker", "year": "1991", "unstructured": "Secker-Walker LM, Craig JM, Hawkins JM, et al. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991; 5: 196\u2013199.", "journal-title": "Leukemia."}, {"key": "11_CR34_11", "first-page": "1449", "volume": "76", "author": "CH Pui", "year": "1990", "unstructured": "Pui CH, Crist WM and Look T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 1990; 76: 1449\u20131463.", "journal-title": "Blood."}, {"key": "11_CR35_11", "doi-asserted-by": "publisher", "first-page": "1179", "DOI": "10.1128/MCB.20.4.1179-1186.2000", "volume": "20", "author": "MS Neshat", "year": "2000", "unstructured": "Neshat MS, Raitano AB, Wang HG, et al. The survival function of the Bcr-Abl onocogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000; 20: 1179\u20131186.", "journal-title": "Mol Cell Biol."}, {"key": "11_CR36_11", "doi-asserted-by": "publisher", "first-page": "2496", "DOI": "10.1038/sj.onc.1203486", "volume": "19", "author": "TS Lin", "year": "2000", "unstructured": "Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000; 19: 2496\u20132504.", "journal-title": "Oncogene."}, {"key": "11_CR37_11", "first-page": "2275", "volume": "55", "author": "T Skorski", "year": "1995", "unstructured": "Skorski T, Nieborowska-Skorska M, Szczylik C, et al. c-RAF-1 Serine/Threonine Kinase Is Required in BCR/ABL-dependent and Normal Hematopoiesis. Cancer Res. 1995; 55: 2275\u20132278.", "journal-title": "Cancer Res."}, {"issue": "5", "key": "11_CR38_11", "doi-asserted-by": "publisher", "first-page": "453", "DOI": "10.1038/ng1343", "volume": "36", "author": "Y Hu", "year": "2004", "unstructured": "Hu Y, Pelletier S, Buchdunger E, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004; 36(5): 453\u2013461.", "journal-title": "Nat Genet."}, {"key": "11_CR39_11", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.7164/antibiotics.30.275", "volume": "30", "author": "S Omura", "year": "1977", "unstructured": "Omura S, Iwai Y, Hirano A, et al. A new alkaloid AM-2282 of Streptomyces origin. Fermentation, isolation and preliminary characterization. J. Antibiotics. 1977; 30: 275.", "journal-title": "J. Antibiotics."}, {"issue": "1", "key": "11_CR40_11", "first-page": "100", "volume": "56", "author": "E Buchdunger", "year": "1996", "unstructured": "Buchdunger E, Zimmerman J, Mett H, et al. Inhibition of the Abl-protein \u2013 tyrosine kinase in vitro and in vivo by a 2 \u2013 phenylaminopyrimidine derivative. Cancer Res.1996; 56(1): 100\u2013104.", "journal-title": "Cancer Res."}, {"key": "11_CR42_11", "doi-asserted-by": "publisher", "first-page": "4500", "DOI": "10.1158/0008-5472.CAN-05-0259", "volume": "65", "author": "T O\u2019Hare", "year": "2005", "unstructured": "Ottman O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 100(7): 2309\u20132315.", "journal-title": "Cancer Res."}, {"key": "11_CR43_11", "doi-asserted-by": "publisher", "first-page": "4500", "DOI": "10.1158/0008-5472.CAN-05-0259", "volume": "65", "author": "T O\u2019Hare", "year": "2005", "unstructured": "Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005; 102(31): 11011\u201311016.", "journal-title": "Cancer Res."}, {"key": "11_CR44_11", "doi-asserted-by": "publisher", "first-page": "4500", "DOI": "10.1158/0008-5472.CAN-05-0259", "volume": "65", "author": "T O\u2019Hare", "year": "2005", "unstructured": "Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell. 2002; 2: 117\u2013125.", "journal-title": "Cancer Res."}, {"key": "11_CR41_11", "doi-asserted-by": "publisher", "first-page": "4500", "DOI": "10.1158/0008-5472.CAN-05-0259", "volume": "65", "author": "T O\u2019Hare", "year": "2005", "unstructured": "O\u2019Hare T, Walters DK, Stoffregen EP et al. In vitro activity if Bcr-Abl inhibitors AMN-107 and BMS \u2013 354825 against clinically relevant imatinib \u2013 resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 4500\u20134505.", "journal-title": "Cancer Res."}, {"issue": "11", "key": "11_CR45_11", "doi-asserted-by": "publisher", "first-page": "2190", "DOI": "10.1038/sj.leu.2402741", "volume": "16", "author": "A Hochhaus", "year": "2002", "unstructured": "Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16(11): 2190\u20132196.", "journal-title": "Leukemia."}, {"key": "11_CR46_11", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1016/j.ccr.2005.01.007", "volume": "7", "author": "E Weisberg", "year": "2005", "unstructured": "Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR/ABL. Cancer Cell. 2005; 7 : 129\u2013141.", "journal-title": "Cancer Cell."}, {"key": "11_CR47_11", "doi-asserted-by": "publisher", "first-page": "876", "DOI": "10.1126/science.1062538", "volume": "293", "author": "ME Gorre", "year": "2001", "unstructured": "Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876\u201380.", "journal-title": "Science."}, {"issue": "21", "key": "11_CR48_11", "first-page": "5995", "volume": "62", "author": "C Ricci", "year": "2002", "unstructured": "Ricci C, Scappini B, Divoky V, et al. Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line. Cancer Res. 2002; 62(21): 5995\u20135998", "journal-title": "Cancer Res."}, {"key": "11_CR49_11", "first-page": "1070", "volume": "96", "author": "FX Mahon", "year": "2000", "unstructured": "Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96: 1070\u20131079.", "journal-title": "Blood."}, {"key": "11_CR50_11", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.1038/sj.leu.2403257", "volume": "18", "author": "T Illmer", "year": "2004", "unstructured": "Illmer T, Schaich M, Platzbecker U, et al. Pglycoprotein- mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells totreatment with imatinib mesylate. Leukemia. 2004; 18: 401\u2013408.", "journal-title": "Leukemia."}, {"key": "11_CR51_11", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.1038/sj.leu.2403257", "volume": "18", "author": "T Illmer", "year": "2004", "unstructured": "Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl Kinase inhibitors for the treatment of chronic myeloid leukemia. Biochim. Biophys. Acta. 2005; 1754: 3\u201313.", "journal-title": "Leukemia."}, {"key": "11_CR52_11", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.1038/sj.leu.2403257", "volume": "18", "author": "T Illmer", "year": "2004", "unstructured": "Verstovsek S, Akin C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leukemia Res. 2006; 30: 1365\u20131370.", "journal-title": "Leukemia."}, {"key": "11_CR53_11", "doi-asserted-by": "publisher", "first-page": "1965", "DOI": "10.1182/blood-2001-12-0181", "volume": "100", "author": "OG Ottman", "year": "2002", "unstructured": "Ottman OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2002; 100: 1965\u20131971.", "journal-title": "Blood."}, {"key": "11_CR54_11", "doi-asserted-by": "publisher", "first-page": "6658", "DOI": "10.1021/jm049486a", "volume": "47", "author": "LJ Lombardo", "year": "2004", "unstructured": "Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2 hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 6658\u20136661.", "journal-title": "J Med Chem."}, {"key": "11_CR55_11", "doi-asserted-by": "publisher", "first-page": "2226", "DOI": "10.1158/0008-5472.CAN-06-3633", "volume": "67", "author": "F Huang", "year": "2007", "unstructured": "Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007; 67: 2226\u20132238.", "journal-title": "Cancer Res."}, {"key": "11_CR56_11", "doi-asserted-by": "publisher", "first-page": "5790", "DOI": "10.1158/0008-5472.CAN-05-4187", "volume": "66", "author": "JS Tokarski", "year": "2006", "unstructured": "Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006; 66: 5790\u20135797.", "journal-title": "Cancer Res."}, {"key": "11_CR57_11", "doi-asserted-by": "publisher", "first-page": "1267", "DOI": "10.1038/sj.leu.2403775", "volume": "19", "author": "C Gambacorti-Passerini", "year": "2005", "unstructured": "Gambacorti-Passerini C, Gasser M, Ahmed S et al. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia. 2005; 19: 1267\u20131269.", "journal-title": "Leukemia."}, {"issue": "3", "key": "11_CR58_11", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.3324/haematol.10822", "volume": "92", "author": "S Soverini", "year": "2007", "unstructured": "Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Hematologica. 2007; 92(3): 401\u2013404.", "journal-title": "Hematologica."}, {"key": "11_CR59_11", "unstructured": "Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4 \u2013 Anilino \u2013 3 \u2013 quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K652 Xenografts in Nude Mice. Cancer Res. 2003."}, {"issue": "23", "key": "11_CR60_11", "doi-asserted-by": "publisher", "first-page": "11314", "DOI": "10.1158/0008-5472.CAN-06-1199", "volume": "66", "author": "M Puttini", "year": "2006", "unstructured": "Puttini M, Coluccia AML, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib \u2013 resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006; 66(23): 11314\u201311322.", "journal-title": "Cancer Res."}, {"key": "11_CR61_11", "doi-asserted-by": "publisher", "first-page": "3948", "DOI": "10.1182/blood-2005-06-2209", "volume": "106", "author": "S Kimura", "year": "2005", "unstructured": "Soverini S, Tasco T, Grafone S, et al. Binding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase. J Clin Oncol (2007) ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: abstract 7049.", "journal-title": "Blood."}, {"key": "11_CR62_11", "doi-asserted-by": "publisher", "first-page": "3948", "DOI": "10.1182/blood-2005-06-2209", "volume": "106", "author": "S Kimura", "year": "2005", "unstructured": "Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005; 106: 3948\u20133954.", "journal-title": "Blood."}, {"key": "11_CR63_11", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.4137/117739010700200008", "volume": "2", "author": "T Niwa", "year": "2007", "unstructured": "Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl dual tyrosine kinase inhibitor. Anal Chem Insights. 2007; 2: 93\u2013106.", "journal-title": "Anal Chem Insights."}, {"issue": "6", "key": "11_CR64_11", "doi-asserted-by": "publisher", "first-page": "980", "DOI": "10.1016/j.leukres.2007.11.008", "volume": "32", "author": "Y Deguchi", "year": "2008", "unstructured": "Deguchi Y, Shinya K, Ashihara E, et al. Compartison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib \u2013 resistant cell lines. Leuk Res. 2008; 32(6): 980\u2013983.", "journal-title": "Leuk Res."}, {"issue": "24", "key": "11_CR65_11", "doi-asserted-by": "publisher", "first-page": "2542", "DOI": "10.1056/NEJMoa055104", "volume": "354", "author": "H Kantarjian", "year": "2006", "unstructured": "Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome \u2013 Positive ALL. NEJM. 2006; 354(24): 2542\u20132551.", "journal-title": "NEJM."}, {"issue": "7", "key": "11_CR66_11", "doi-asserted-by": "publisher", "first-page": "1357", "DOI": "10.1124/dmd.107.018267", "volume": "36", "author": "LJ Christopher", "year": "2008", "unstructured": "Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008, 36(7): 1357\u20131364.", "journal-title": "Drug Metab Dispos."}, {"issue": "10", "key": "11_CR67_11", "doi-asserted-by": "publisher", "first-page": "1503", "DOI": "10.1124/dmd.105.004283", "volume": "33", "author": "HP Gschwind", "year": "2005", "unstructured": "Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos. 2005; 33 (10): 1503\u20131512.", "journal-title": "Drug Metab Dispos."}, {"key": "11_CR68_11", "unstructured": "Tanaka C, Smith T, KantarJlan H, et al. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, In healthy subjects and patients with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ ALL). J Clin Oncol. 2006; 24(Suppl 18): b3095. Abstract. 45."}, {"issue": "3", "key": "11_CR69_11", "doi-asserted-by": "publisher", "first-page": "365", "DOI": "10.1007/s00280-007-0478-8", "volume": "61", "author": "AV Kamath", "year": "2008", "unstructured": "Kamath AV, Wang J, Lee FY, et al. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008; 61 (3): 365\u2013376.", "journal-title": "Cancer Chemother Pharmacol."}, {"issue": "2", "key": "11_CR70_11", "first-page": "625", "volume": "9", "author": "C Gambacorti-Passerini", "year": "2003", "unstructured": "Gambacorti-Passerini C, Zucchetti M, Russo D et al., Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003; 9(2): 625\u2013632.", "journal-title": "Clin Cancer Res."}, {"key": "11_CR71_11", "doi-asserted-by": "publisher", "first-page": "2525", "DOI": "10.1158/1078-0432.CCR-03-0155", "volume": "10", "author": "K Neville", "year": "2004", "unstructured": "Neville K, Parise RA, Thompson P, et al. Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates. Clin Cancer Res. 2004; 10: 2525\u20132529.", "journal-title": "Clin Cancer Res."}, {"issue": "3", "key": "11_CR72_11", "doi-asserted-by": "publisher", "first-page": "1085", "DOI": "10.1124/jpet.102.045260", "volume": "304", "author": "H Dai", "year": "2003", "unstructured": "Dai H, Marbach P, Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 2003; 304(3): 1085\u20131092.", "journal-title": "J Pharmacol Exp Ther."}, {"key": "11_CR73_11", "first-page": "4887", "volume": "106", "author": "M Kagan", "year": "2005", "unstructured": "Kagan M, Tran P, Fischer V, et al. Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN1 07, a novel amlnopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects. Blood. 2005; 106: 4887.", "journal-title": "Blood."}, {"issue": "24", "key": "11_CR74_11", "doi-asserted-by": "publisher", "first-page": "7394", "DOI": "10.1158/1078-0432.CCR-07-0346", "volume": "13", "author": "NP Erp van", "year": "2007", "unstructured": "van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. 2007; 13(24): 7394\u2013400.", "journal-title": "Clin Cancer Res."}, {"key": "11_CR75_11", "doi-asserted-by": "publisher", "first-page": "1038", "DOI": "10.1056/NEJM200104053441402", "volume": "344", "author": "BJ Druker", "year": "2001", "unstructured": "Druker BJ, Sawyers CL, Kantarijan H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Eng J Med. 2001; 344: 1038\u20131042.", "journal-title": "N Eng J Med."}, {"key": "11_CR76_11", "doi-asserted-by": "publisher", "first-page": "1495", "DOI": "10.1182/blood-2003-01-0154", "volume": "103", "author": "B Wassman", "year": "2004", "unstructured": "Wassman B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood. 2004; 103: 1495\u20131498.", "journal-title": "Blood."}, {"issue": "24", "key": "11_CR77_11", "doi-asserted-by": "crossref", "first-page": "2351", "DOI": "10.1056/NEJMoa055229", "volume": "354", "author": "M Talpaz", "year": "2006", "unstructured": "Talpaz M, Shah N, Kantarjian H, et al. Dastinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias. N Eng J Med. 2006; 354(24): 2351\u20132541.", "journal-title": "N Eng J Med"}, {"key": "11_CR78_11", "first-page": "286", "volume": "108", "author": "H Dombret", "year": "2006", "unstructured": "Dombret H, Ottman OG, Rosti G, et al. Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or \u2013intolerant (im-i): updated results from the CA180-015 START-L study. Blood. (Suppl.) 2006; 108: 286.", "journal-title": "Blood. (Suppl.)"}, {"key": "11_CR79_11", "first-page": "473", "volume": "110", "author": "C Gambacorti-Passerini", "year": "2007", "unstructured": "Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, et al. Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL. Blood (ASH Annual Meeting Abstracts). Nov 2007; 110: 473.", "journal-title": "Nov"}, {"key": "11_CR80_11", "unstructured": "Gambacorti-Passerini C, Kantarjian HM, Baccarani M, et al. Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. Journal of Clinical Oncology. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).", "DOI": "10.1200/jco.2008.26.15_suppl.7049", "doi-asserted-by": "crossref"}, {"key": "11_CR81_11", "unstructured": "Kantarjian HM, Cortes J, le Coutre P, et al. A Phase I Study of INNO-406 in Patients with advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors. Blood (ASH Meeting Abstracts). 2007; 110: abstract 469."}, {"key": "11_CR82_11", "first-page": "2665", "volume": "116", "author": "H Kantarjian", "year": "2010", "unstructured": "Kantarjian H, le Coutre P, Cortes J, et al. Phase I study of INNO \u2013 406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome \u2013 positive leukemias after imatinib resistance or intolerance. Cancer. 2010;116: 2665\u20132672.", "journal-title": "Cancer."}, {"key": "11_CR83_11", "doi-asserted-by": "publisher", "first-page": "994", "DOI": "10.1056/NEJMoa022457", "volume": "348", "author": "SG O\u2019Brien", "year": "2003", "unstructured": "O\u2019Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994\u20131004.", "journal-title": "N Engl J Med."}, {"key": "11_CR84_11", "unstructured": "Secker-Walker LM, Prentice HG, Durrant J, et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trial UKALL XA \u2013 MRC Adult Leukemia Working Party. Br J Haematol. 1997; 96: 601\u2013610.", "DOI": "10.1046/j.1365-2141.1997.d01-2053.x", "doi-asserted-by": "crossref"}, {"key": "11_CR85_11", "first-page": "3983", "volume": "93", "author": "M Wetzler", "year": "1999", "unstructured": "Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience. Blood. 1999; 93: 3983\u20133993.", "journal-title": "Blood."}, {"key": "11_CR86_11", "doi-asserted-by": "publisher", "first-page": "863", "DOI": "10.1182/blood.V99.3.863", "volume": "99", "author": "L Annino", "year": "2002", "unstructured": "Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002; 99: 863\u2013871.", "journal-title": "Blood."}, {"key": "11_CR87_11", "unstructured": "Thomas DA, Kantarjian HM, Cortes JE, et al. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL). JCO ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2008; 26, 15S:7019.", "DOI": "10.1200/jco.2008.26.15_suppl.7019", "doi-asserted-by": "crossref"}, {"issue": "3", "key": "11_CR88_11", "doi-asserted-by": "publisher", "first-page": "460", "DOI": "10.1200/JCO.2005.03.2177", "volume": "24", "author": "M Yanada", "year": "2006", "unstructured": "Yanada M, Takeuchi J, Sugiura I, et al. High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006; 24(3): 460\u2013466.", "journal-title": "J Clin Oncol"}, {"key": "11_CR89_11", "doi-asserted-by": "publisher", "first-page": "1469", "DOI": "10.1182/blood-2005-11-4386", "volume": "108", "author": "B Wassmann", "year": "2006", "unstructured": "Wassman B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006; 108: 1469\u20131477.", "journal-title": "Blood."}, {"key": "11_CR90_11", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1182/blood-2008-02-078170", "volume": "112", "author": "Y Chalandon", "year": "2008", "unstructured": "Chalandon Y, Thomas X, Hayette S, et al. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia [abstract]. Blood. 2008; 112: 11.", "journal-title": "Blood."}, {"issue": "4", "key": "11_CR91_11", "doi-asserted-by": "crossref", "first-page": "1480", "DOI": "10.1182/blood-2006-03-011908", "volume": "109", "author": "A Labarthe de", "year": "2007", "unstructured": "de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007; 109(4): 1480\u20131413.", "journal-title": "Blood."}, {"issue": "9", "key": "11_CR92_11", "doi-asserted-by": "publisher", "first-page": "3676", "DOI": "10.1182/blood-2006-10-052746", "volume": "109", "author": "M Vignetti", "year": "2007", "unstructured": "Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007; 109(9): 3676\u20133678.", "journal-title": "Blood."}, {"key": "11_CR93_11", "unstructured": "Ribera J-M, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial Hematologica. 2010; 95(1): 87\u201395."}, {"key": "11_CR94_11", "doi-asserted-by": "publisher", "first-page": "5175", "DOI": "10.1200/JCO.2008.21.2514", "volume": "27", "author": "KR Schultz", "year": "2009", "unstructured": "Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: A Children\u2019s Oncology Group study. J Clin Oncol. 2009; 27: 5175\u20135181.", "journal-title": "J Clin Oncol."}, {"key": "11_CR95_11", "unstructured": "Ravandi F, Thomas D, Kantarjian H, et al. Pjase II study of combination of hyperCVAD in frontline therapy of patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2008; 112. abstract 2921."}, {"key": "11_CR96_11", "unstructured": "Rousselot P, Cayuela J-M, Recher C, et al. Dasatinib (Sprycel (R) and chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patietns Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL)). Blood (ASH Annual Meeting Abstracts). 2008; 112: abstract 2920."}, {"issue": "2", "key": "11_CR97_11", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1016/j.bcp.2009.04.002", "volume": "78", "author": "AK Tiwari", "year": "2009", "unstructured": "Tiwari AK, Sodani K, Wang SR, et al. Nilotinib (AMN-107, Tasigna) reverses multidrug resistnce by inhibiting the activity of the ABCB1.Pgp and ABCG2/BCRP/MXR transporters. Biochemical Pharmacology. 2009; 78(2): 153\u2013161.", "journal-title": "Biochemical Pharmacology."}, {"key": "11_CR98_11", "doi-asserted-by": "crossref", "first-page": "658", "DOI": "10.1038/leu.2009.242", "volume": "24", "author": "DK Hiwase", "year": "2010", "unstructured": "Hiwase DK, White D, Zrim S, et al. Nilotinib \u2013 mediated inhibition of ABCB1 increases intracellular concentration of Dasatinib in CML cells: implications for combination TKI therapy. Leukemia. 2010; 24: 658\u2013660.", "journal-title": "Leukemia"}, {"key": "11_CR99_11", "unstructured": "Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358),a multi-kinase Aurora inhibitor, elicits clinical benefit in advanced myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts). 2009; 114: abstract 864."}, {"key": "11_CR100_11", "unstructured": "Foran JM, Ravandi F, O\u2019Brien SM, et al, Phase I and pharmacodynamic trials of AT9283, an aurora kinase inhibitor, in refractory leukemia. J Clin Oncol ASCO Annual Meeting Proceedings (Post - Meeting Edition). 2008; 26: abstract 2518.", "DOI": "10.1200/jco.2008.26.15_suppl.2518", "doi-asserted-by": "crossref"}, {"key": "11_CR101_11", "unstructured": "Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/Aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood (ASH Annual Meeting Abstracts). 2008; 112(11): abstract 3232."}, {"key": "11_CR102_11", "doi-asserted-by": "crossref", "first-page": "758", "DOI": "10.1038/nature05690", "volume": "446", "author": "CG Mullighan", "year": "2007", "unstructured": "Mullighan CG, Goorha S, Radtke I, et al. Genome \u2013 wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446: 758\u2013764.", "journal-title": "Nature"}, {"issue": "4", "key": "11_CR103_11", "doi-asserted-by": "crossref", "first-page": "751", "DOI": "10.1084/jem.20072182", "volume": "205", "author": "E Flex", "year": "2008", "unstructured": "Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med, 2008; 205(4): 751\u2013758.", "journal-title": "J Exp Med"}, {"key": "11_CR104_11", "unstructured": "Verstovsek S, Kantarjian H, Pardanani A, et al. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF) Blood. 2007; 110: abstract 558.", "DOI": "10.1200/jco.2008.26.15_suppl.7004", "doi-asserted-by": "crossref"}, {"key": "11_CR105_11", "unstructured": "Verstovsek S, Kantarjian, HM, Pardanani AD, et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ET-MF) Blood. 2008; 112: abstract 1762.", "DOI": "10.1200/jco.2008.26.15_suppl.7004", "doi-asserted-by": "crossref"}, {"key": "11_CR106_11", "first-page": "99", "volume": "112", "author": "AR Moliterno", "year": "2008", "unstructured": "Moliterno AR, Roboz GJ, Carroll M, et al. An open-label study of CEP- 701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. Blood. 2008; 112: abstract. 99.", "journal-title": "Blood"}, {"key": "11_CR107_11", "unstructured": "Verstovsek S, Kantarjian H, Mesa RA, et al. Long \u2013 Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety. 51st American Society of Hematology Annual Meeting. 2009; abstract 756."}, {"issue": "4", "key": "11_CR108_11", "first-page": "588", "volume": "10", "author": "HG Drexler", "year": "1996", "unstructured": "Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand in leukemic cells Leukemia. 1996; 10(4): 588\u2013599.", "journal-title": "Leukemia."}], "container-title": ["New Agents for the Treatment of Acute Lymphoblastic Leukemia"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4419-8459-3_11", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 23]], "date-time": "2019-05-23T07:25:59Z", "timestamp": 1558596359000}, "score": 21.61687, "issued": {"date-parts": [[2011]]}, "ISBN": ["9781441984586", "9781441984593"], "references-count": 109, "URL": "http://dx.doi.org/10.1007/978-1-4419-8459-3_11", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T01:10:30Z", "timestamp": 1575508230702}, "reference-count": 0, "publisher": "OAE Publishing Inc.", "content-domain": {"domain": ["oaepublish.com"], "crossmark-restriction": false}, "short-container-title": ["CDR"], "DOI": "10.20517/cdr.2019.50", "type": "journal-article", "created": {"date-parts": [[2019, 9, 4]], "date-time": "2019-09-04T12:26:49Z", "timestamp": 1567600009000}, "update-policy": "http://dx.doi.org/10.20517/oae.crossmark.policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology"], "prefix": "10.20517", "author": [{"given": "Angela", "family": "Mweempwa", "sequence": "first", "affiliation": []}, {"given": "Michelle K.", "family": "Wilson", "sequence": "additional", "affiliation": []}], "member": "8410", "published-online": {"date-parts": [[2019]]}, "container-title": ["Cancer  Drug Resistance"], "deposited": {"date-parts": [[2019, 9, 4]], "date-time": "2019-09-04T12:26:50Z", "timestamp": 1567600010000}, "score": 21.488886, "issued": {"date-parts": [[2019]]}, "references-count": 0, "URL": "http://dx.doi.org/10.20517/cdr.2019.50"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T17:49:57Z", "timestamp": 1574531397697}, "reference-count": 132, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 7, 1]], "date-time": "2011-07-01T00:00:00Z", "timestamp": 1309478400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cytokine & Growth Factor Reviews"], "published-print": {"date-parts": [[2011, 7]]}, "DOI": "10.1016/j.cytogfr.2011.06.001", "type": "journal-article", "created": {"date-parts": [[2011, 8, 2]], "date-time": "2011-08-02T06:37:32Z", "timestamp": 1312267052000}, "source": "Crossref", "is-referenced-by-count": 51, "title": ["CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications"], "prefix": "10.1016", "author": [{"given": "Mingli", "family": "Liu", "sequence": "first", "affiliation": []}, {"given": "Shanchun", "family": "Guo", "sequence": "additional", "affiliation": []}, {"given": "Jacqueline M.", "family": "Hibbert", "sequence": "additional", "affiliation": []}, {"given": "Vidhan", "family": "Jain", "sequence": "additional", "affiliation": []}, {"given": "Neeru", "family": "Singh", "sequence": "additional", "affiliation": []}, {"given": "Nana O.", "family": "Wilson", "sequence": "additional", "affiliation": []}, {"given": "Jonathan K.", "family": "Stiles", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cytokine & Growth Factor Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359610111000293?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359610111000293?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 13]], "date-time": "2019-06-13T17:20:30Z", "timestamp": 1560446430000}, "score": 21.146708, "issued": {"date-parts": [[2011, 7]]}, "references-count": 132, "alternative-id": ["S1359610111000293"], "URL": "http://dx.doi.org/10.1016/j.cytogfr.2011.06.001", "ISSN": ["1359-6101"], "issn-type": [{"value": "1359-6101", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T12:02:38Z", "timestamp": 1574164958142}, "reference-count": 30, "publisher": "Informa UK Limited", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Review of Anticancer Therapy"], "published-print": {"date-parts": [[2002, 10]]}, "DOI": "10.1586/14737140.2.5.593", "type": "journal-article", "created": {"date-parts": [[2005, 1, 13]], "date-time": "2005-01-13T12:56:05Z", "timestamp": 1105620965000}, "page": "593-603", "source": "Crossref", "is-referenced-by-count": 22, "title": ["Potential of DMXAA combination therapy for solid tumors"], "prefix": "10.1586", "volume": "2", "author": [{"given": "Bruce C", "family": "Baguley", "sequence": "first", "affiliation": []}, {"given": "William R", "family": "Wilson", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 1, 10]]}, "reference": [{"key": "CIT0002", "author": "Auerbach W Auerbach R. Angiogenesis inhibition", "volume": "63", "first-page": "265", "year": "1994", "journal-title": "Pharmacol Ther", "DOI": "10.1016/0163-7258(94)90027-2", "doi-asserted-by": "crossref"}, {"key": "CIT0009", "author": "Starnes CO", "volume": "357", "first-page": "11", "year": "1992", "journal-title": "Nature", "DOI": "10.1038/357011a0", "doi-asserted-by": "crossref"}, {"key": "CIT0010", "author": "Hobohm U", "volume": "50", "first-page": "391", "year": "2001", "journal-title": "Cancer Immunol Immunother"}, {"key": "CIT0011", "author": "Old U", "volume": "230", "first-page": "630", "year": "1985", "journal-title": "Science", "DOI": "10.1126/science.2413547", "doi-asserted-by": "crossref"}, {"key": "CIT0012", "author": "Carswell EA", "volume": "25", "first-page": "3666", "year": "1975", "journal-title": "An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA"}, {"key": "CIT0013", "author": "Lienard D", "volume": "10", "first-page": "52", "year": "1992", "journal-title": "' Gun. aryl"}, {"key": "CIT0019", "author": "Evelhoch JL", "volume": "48", "first-page": "4749", "year": "1988", "journal-title": "Cancer Res"}, {"key": "CIT0023", "author": "Kerr DJ", "volume": "25", "first-page": "1271", "year": "1989", "journal-title": "Eurj Cancer Clin. aryl", "DOI": "10.1016/0277-5379(89)90072-2", "doi-asserted-by": "crossref"}, {"key": "CIT0024", "author": "ZWi U", "volume": "6", "first-page": "79", "year": "1994", "journal-title": "Oncol Res"}, {"key": "CIT0042", "author": "Ching LM", "volume": "54", "first-page": "870", "year": "1994", "journal-title": "Cancer Res"}, {"key": "CIT0045", "author": "Ludford RJ", "volume": "6", "first-page": "411", "year": "1945", "journal-title": "j Natl Cancer Inst"}, {"key": "CIT0046", "author": "Hill SA", "volume": "29", "first-page": "1320", "year": "1993", "journal-title": "Eur j Cancer", "DOI": "10.1016/0959-8049(93)90082-Q", "doi-asserted-by": "crossref"}, {"key": "CIT0047", "author": "Hill SA", "volume": "345", "first-page": "417", "year": "1994", "journal-title": "Adv. Exp. Med. Biol", "DOI": "10.1007/978-1-4615-2468-7_55", "doi-asserted-by": "crossref"}, {"key": "CIT0050", "author": "Schiff PB", "volume": "277", "first-page": "665", "year": "1979", "journal-title": "Promotion of microtubule assembly in vitro by Taxol. Nature"}, {"key": "CIT0066", "author": "Chaplin DJ", "volume": "74", "first-page": "S86\u2014S88", "year": "1996", "journal-title": "BE j Cancer"}, {"key": "CIT0068", "author": "Tannock IF", "volume": "351", "first-page": "9", "year": "1998", "journal-title": "Lancet", "DOI": "10.1016/S0140-6736(98)90327-0", "doi-asserted-by": "crossref"}, {"issue": "4", "key": "CIT0071", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1080/028418601750288235", "volume": "40", "author": "Horsman MR", "year": "2001", "journal-title": "Acta Oncol"}, {"key": "CIT0072", "author": "Schreck R", "volume": "17", "first-page": "221", "year": "1992", "journal-title": "Nuclear factor kappa B \u2014 an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free. Raclic. Res. Commun"}, {"key": "CIT0078", "author": "Wilson WR", "volume": "22", "first-page": "881", "year": "1995", "journal-title": "Clin. Exp. Pharmacol Physiol", "DOI": "10.1111/j.1440-1681.1995.tb01956.x", "doi-asserted-by": "crossref"}, {"key": "CIT0079", "author": "Wilson WR", "volume": "74", "first-page": "S43\u2014S47", "year": "1996", "journal-title": "U Cancer"}, {"key": "CIT0081", "author": "Wilson WR", "volume": "22", "first-page": "693", "year": "1992", "journal-title": "Bis- bioreductive agents as hypoxia-selective cytotoxins \u2014 nitracrine N-oxide. hit. j Racliat. Dna. Biol. Phys"}, {"key": "CIT0083", "author": "Sum BG", "volume": "29", "first-page": "311", "year": "1994", "journal-title": "Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? Int. J Racliat. Oncol Biol. Phys"}, {"key": "CIT0084", "author": "Baguley BC", "volume": "16", "first-page": "97", "year": "2002", "journal-title": "BioDrugs", "DOI": "10.2165/00063030-200216020-00003", "doi-asserted-by": "crossref"}, {"issue": "5288", "key": "CIT0085", "doi-asserted-by": "crossref", "first-page": "784", "DOI": "10.1126/science.274.5288.784", "volume": "274", "author": "Wang CY", "year": "1996", "journal-title": "Science"}, {"key": "CIT0086", "author": "Wilson WR", "volume": "46", "first-page": "706", "year": "2000", "journal-title": "int. j Racliat. Oncol Biol. Phys"}, {"key": "CIT0087", "DOI": "10.1002/ijc.10316", "doi-asserted-by": "publisher"}, {"issue": "6", "key": "CIT0088", "first-page": "830", "volume": "57", "author": "Pedley RB", "year": "1994", "journal-title": "liiLj Cancer"}, {"key": "CIT0093", "DOI": "10.1073/pnas.91.9.4082", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "CIT0099", "doi-asserted-by": "crossref", "first-page": "59", "DOI": "10.3109/08923979609007110", "volume": "18", "author": "Shannon EJ", "year": "1996", "journal-title": "Immunopharmacol Immunotoxicol"}, {"issue": "3", "key": "CIT0107", "first-page": "165", "volume": "30", "author": "Ramu A", "year": "1992", "journal-title": "Pharmacol"}], "container-title": ["Expert Review of Anticancer Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1586/14737140.2.5.593", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 16]], "date-time": "2017-06-16T14:53:18Z", "timestamp": 1497624798000}, "score": 20.97752, "issued": {"date-parts": [[2002, 10]]}, "references-count": 30, "journal-issue": {"published-online": {"date-parts": [[2014, 1, 10]]}, "published-print": {"date-parts": [[2002, 10]]}, "issue": "5"}, "alternative-id": ["10.1586/14737140.2.5.593"], "URL": "http://dx.doi.org/10.1586/14737140.2.5.593", "relation": {"cites": []}, "ISSN": ["1473-7140", "1744-8328"], "issn-type": [{"value": "1473-7140", "type": "print"}, {"value": "1744-8328", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T00:11:22Z", "timestamp": 1574295082968}, "reference-count": 0, "publisher": "Elsevier", "isbn-type": [{"value": "9780750646253", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2000]]}, "DOI": "10.1016/b978-075064625-3/50046-9", "type": "book-chapter", "created": {"date-parts": [[2007, 5, 25]], "date-time": "2007-05-25T05:34:47Z", "timestamp": 1180071287000}, "page": "1-6", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Constant-potential charging"], "prefix": "10.1016", "author": [{"given": "TR", "family": "Crompton", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Battery Reference Book"], "deposited": {"date-parts": [[2019, 1, 7]], "date-time": "2019-01-07T06:51:36Z", "timestamp": 1546843896000}, "score": 20.898203, "issued": {"date-parts": [[2000]]}, "ISBN": ["9780750646253"], "references-count": 0, "URL": "http://dx.doi.org/10.1016/b978-075064625-3/50046-9"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T20:00:06Z", "timestamp": 1574539206812}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 4, 15]]}, "DOI": "10.1158/1538-7445.am2013-4462", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:46:55Z", "timestamp": 1408056415000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 4462: Resistance to selective kinase inhibitors upon epithelial to mesenchymal transition."], "prefix": "10.1158", "author": [{"given": "Catherine R.", "family": "Wilson", "sequence": "first", "affiliation": []}, {"given": "Katrina", "family": "Nicholes", "sequence": "additional", "affiliation": []}, {"given": "Daisy", "family": "Bustos", "sequence": "additional", "affiliation": []}, {"given": "Eva", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "Lily", "family": "Shi", "sequence": "additional", "affiliation": []}, {"given": "Donald", "family": "Kirkpatrick", "sequence": "additional", "affiliation": []}, {"given": "Jeffrey", "family": "Settleman", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 18]]}, "event": {"name": "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC"}, "container-title": ["Experimental and Molecular Therapeutics"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2013-4462", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T20:15:17Z", "timestamp": 1558210517000}, "score": 20.726728, "issued": {"date-parts": [[2013, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2013-4462"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2013-4462"}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T11:35:55Z", "timestamp": 1574854555791}, "publisher-location": "Washington, DC", "reference-count": 0, "publisher": "Island Press/Center for Resource Economics", "isbn-type": [{"value": "9781610919883", "type": "print"}, {"value": "9781610918930", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 1, 1]], "date-time": "2018-01-01T00:00:00Z", "timestamp": 1514764800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018]]}, "DOI": "10.5822/978-1-61091-893-0_1", "type": "book-chapter", "created": {"date-parts": [[2018, 7, 17]], "date-time": "2018-07-17T06:27:23Z", "timestamp": 1531808843000}, "page": "1-13", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Introduction: Resilience or Resistance?"], "prefix": "10.5822", "author": [{"given": "Barbara", "family": "Wilson", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Resilience for All"], "link": [{"URL": "http://link.springer.com/content/pdf/10.5822/978-1-61091-893-0_1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 7, 17]], "date-time": "2018-07-17T06:27:24Z", "timestamp": 1531808844000}, "score": 20.657665, "issued": {"date-parts": [[2018]]}, "ISBN": ["9781610919883", "9781610918930"], "references-count": 0, "URL": "http://dx.doi.org/10.5822/978-1-61091-893-0_1"}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:18:46Z", "timestamp": 1575530326745}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "2", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1982, 8, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>A population of macrophage progenitor cells, with high proliferative potential, has recently been demonstrated in postfluorouracil-treated and normal mouse bone marrow (BM) in vitro, when the newly discovered growth factor (synergistic activity, SA) is combined with a macrophage colony-stimulating factor (CSF) as a proliferative stimulus. SA, shown to be present in human spleen and placental conditioned media (HSCM and HPCM, respectively) have been studied and found to be unstable to trypsin digestion and to heating at 50 degrees C or above; stable between pH 4 and 9; nonadherent to Con-A-Sepharose; and to have an isoelectric point between pH 5 and 5.8 and a molecular weight of between 14,000 and 21,000 as indicated by gel filtration chromatography. SAs from both HSCM and HPCM have been purified 89- and 122-fold, respectively, by precipitation of extraneous proteins at pH 5 followed by chromatographing twice on Sephacryl S200. Neither of these partially purified SAs contain any CSF for mouse BM. These results indicate that the SAs from HSCM and HPCM may be closely related and that they are structurally different from CSFs derived from various murine sources that have been shown to be stable to proteolytic enzymes and heat.</jats:p>", "DOI": "10.1182/blood.v60.2.503.503", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T06:44:16Z", "timestamp": 1570949056000}, "page": "503-508", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Partial purification and characterization of a growth factor for macrophage progenitor cells with high proliferative potential in mouse bone marrow"], "prefix": "10.1182", "volume": "60", "author": [{"given": "AB", "family": "Kriegler", "sequence": "first", "affiliation": []}, {"given": "TR", "family": "Bradley", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Januszewicz", "sequence": "additional", "affiliation": []}, {"given": "GS", "family": "Hodgson", "sequence": "additional", "affiliation": []}, {"given": "EF", "family": "Elms", "sequence": "additional", "affiliation": []}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/60/2/503/589384/503.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/60/2/503/589384/503.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T00:59:04Z", "timestamp": 1574211544000}, "score": 20.109901, "issued": {"date-parts": [[1982, 8, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1982, 8, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1182/blood.v60.2.503.503", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:39:08Z", "timestamp": 1575527948946}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "2", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1982, 8, 1]]}, "abstract": "<jats:p>A population of macrophage progenitor cells, with high proliferative potential, has recently been demonstrated in postfluorouracil-treated and normal mouse bone marrow (BM) in vitro, when the newly discovered growth factor (synergistic activity, SA) is combined with a macrophage colony-stimulating factor (CSF) as a proliferative stimulus. SA, shown to be present in human spleen and placental conditioned media (HSCM and HPCM, respectively) have been studied and found to be unstable to trypsin digestion and to heating at 50 degrees C or above; stable between pH 4 and 9; nonadherent to Con-A-Sepharose; and to have an isoelectric point between pH 5 and 5.8 and a molecular weight of between 14,000 and 21,000 as indicated by gel filtration chromatography. SAs from both HSCM and HPCM have been purified 89- and 122-fold, respectively, by precipitation of extraneous proteins at pH 5 followed by chromatographing twice on Sephacryl S200. Neither of these partially purified SAs contain any CSF for mouse BM. These results indicate that the SAs from HSCM and HPCM may be closely related and that they are structurally different from CSFs derived from various murine sources that have been shown to be stable to proteolytic enzymes and heat.</jats:p>", "DOI": "10.1182/blood.v60.2.503.bloodjournal602503", "type": "journal-article", "created": {"date-parts": [[2019, 10, 10]], "date-time": "2019-10-10T04:51:31Z", "timestamp": 1570683091000}, "page": "503-508", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Partial purification and characterization of a growth factor for macrophage progenitor cells with high proliferative potential in mouse bone marrow"], "prefix": "10.1182", "volume": "60", "author": [{"given": "AB", "family": "Kriegler", "sequence": "first", "affiliation": []}, {"given": "TR", "family": "Bradley", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Januszewicz", "sequence": "additional", "affiliation": []}, {"given": "GS", "family": "Hodgson", "sequence": "additional", "affiliation": []}, {"given": "EF", "family": "Elms", "sequence": "additional", "affiliation": []}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/60/2/503/211125/503.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/60/2/503/211125/503.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T04:55:13Z", "timestamp": 1573880113000}, "score": 20.109901, "issued": {"date-parts": [[1982, 8, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1982, 8, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1182/blood.v60.2.503.bloodjournal602503", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T01:34:21Z", "timestamp": 1575164061193}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1996, 2, 1]], "date-time": "1996-02-01T00:00:00Z", "timestamp": 823132800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Gastroenterology"], "published-print": {"date-parts": [[1996, 2]]}, "DOI": "10.1053/gast.1996.v110.pm8566594", "type": "journal-article", "created": {"date-parts": [[2005, 7, 29]], "date-time": "2005-07-29T17:58:00Z", "timestamp": 1122659880000}, "page": "469-477", "source": "Crossref", "is-referenced-by-count": 32, "title": ["Epidermal growth factor inhibits carbachol-stimulated canine parietal cell function via protein kinase C"], "prefix": "10.1053", "volume": "110", "author": [{"given": "L", "family": "Wang", "sequence": "first", "affiliation": []}, {"given": "EJ", "family": "Wilson", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Osburn", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "DelValle", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Gastroenterology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0016508596000789?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0016508596000789?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 24]], "date-time": "2019-01-24T04:58:11Z", "timestamp": 1548305891000}, "score": 20.045034, "issued": {"date-parts": [[1996, 2]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1996, 2]]}, "issue": "2"}, "alternative-id": ["S0016508596000789"], "URL": "http://dx.doi.org/10.1053/gast.1996.v110.pm8566594", "ISSN": ["0016-5085"], "issn-type": [{"value": "0016-5085", "type": "print"}], "subject": ["Gastroenterology"]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T18:51:39Z", "timestamp": 1575139899694}, "reference-count": 0, "publisher": "CSIRO Publishing", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Aust. J. Exp. Agric."], "published-print": {"date-parts": [[1992]]}, "abstract": "<jats:p>Fertilised pastures of 4 varieties of Setaria sphacelata (var. splendida and cvv. Nandi, Narok and Kazungula), pangola grass (Digitaria eriantha ssp. pentzii) and kikuyu grass (Pennisetum clandestinum cv. Whittet) were grazed rotationally over a 3-year period at Beerwah, south-eastern Queensland. Each variety was grazed on a 5-weekly rotation by 2 leaders for 7 days; a follower herd including 2 testers grazed the regrowth for 7 days. The numbers of followers were subjectively adjusted weekly, depending on feed available. The experiment was designed to provide adequate quantities of forage of maximum potential quality to the leaders throughout the year. There were large and frequently consistent differences between the grasses in yield and its various components, leafiness, leaf and forage density, rate of development of leaf dry matter, and time and intensity of flowering under the management system imposed. Of particular interest were the high leaf yield of Narok, high overall yield of Narok and var. splendida, low rate of development of leaf area index of pangola grass and kikuyu grass, and high forage density of kikuyu grass. These differences might be expected to have an effect on pasture quality, carrying capacity and optimal management strategy.</jats:p>", "DOI": "10.1071/ea9920019", "type": "journal-article", "created": {"date-parts": [[2005, 3, 31]], "date-time": "2005-03-31T05:13:23Z", "timestamp": 1112246003000}, "page": "19", "source": "Crossref", "is-referenced-by-count": 6, "title": ["An evaluation of the production potential of six tropical grasses under grazing. 1. Yield and yield components, growth rates and phenology"], "prefix": "10.1071", "volume": "32", "author": [{"given": "JB", "family": "Hacker", "sequence": "first", "affiliation": []}, {"given": "TR", "family": "Evans", "sequence": "additional", "affiliation": []}], "member": "67", "container-title": ["Australian Journal of Experimental Agriculture"], "language": "en", "link": [{"URL": "http://www.publish.csiro.au/EA/pdf/EA9920019", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 22]], "date-time": "2018-11-22T03:40:18Z", "timestamp": 1542858018000}, "score": 20.008518, "issued": {"date-parts": [[1992]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1992]]}, "issue": "1"}, "alternative-id": ["EA9920019"], "URL": "http://dx.doi.org/10.1071/ea9920019", "ISSN": ["0816-1089"], "issn-type": [{"value": "0816-1089", "type": "print"}], "subject": ["General Agricultural and Biological Sciences"]}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T03:54:13Z", "timestamp": 1574826853394}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1997, 10, 1]]}, "DOI": "10.21236/adb233740", "type": "report", "created": {"date-parts": [[2017, 8, 25]], "date-time": "2017-08-25T19:19:11Z", "timestamp": 1503688751000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Optimization of Fibroblast Growth Factor-1 as an Anabolic Agent for Osteoporosis"], "prefix": "10.21236", "author": [{"given": "Wilson H.", "family": "Burgess", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 8, 25]], "date-time": "2017-08-25T19:19:12Z", "timestamp": 1503688752000}, "score": 19.997766, "subtitle": [""], "issued": {"date-parts": [[1997, 10, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/adb233740"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T01:34:23Z", "timestamp": 1574472863427}, "reference-count": 48, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1684, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 2]]}, "DOI": "10.1111/j.1476-5381.2010.01099.x", "type": "journal-article", "created": {"date-parts": [[2010, 10, 29]], "date-time": "2010-10-29T17:29:43Z", "timestamp": 1288373383000}, "page": "785-791", "source": "Crossref", "is-referenced-by-count": 58, "title": ["Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors"], "prefix": "10.1111", "volume": "162", "author": [{"given": "Devesh", "family": "Mewar", "sequence": "first", "affiliation": []}, {"given": "Anthony G", "family": "Wilson", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 1, 21]]}, "reference": [{"key": "10.1111/j.1476-5381.2010.01099.x-BIB3|cit1", "doi-asserted-by": "crossref", "first-page": "921", "DOI": "10.1136/ard.2006.065615", "article-title": "Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis", "volume": "66", "author": "Bartelds", "year": "2007", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "817", "DOI": "10.1136/ard.2009.112847", "article-title": "Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study", "volume": "69", "author": "Bartelds", "year": "2010", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB4|cit3", "doi-asserted-by": "crossref", "first-page": "3782", "DOI": "10.1002/art.22214", "article-title": "Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab", "volume": "54", "author": "Bendtzen", "year": "2006", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB5|cit4", "doi-asserted-by": "crossref", "first-page": "2447", "DOI": "10.1002/art.21197", "article-title": "Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept", "volume": "52", "author": "Braun", "year": "2005", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB6|cit5", "doi-asserted-by": "crossref", "first-page": "42", "DOI": "10.1002/art.20711", "article-title": "C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept", "volume": "52", "author": "Buch", "year": "2005", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB7|cit6", "author": "Coulthard", "year": "2010", "article-title": "Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB8|cit7", "first-page": "1849", "article-title": "Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy", "volume": "62", "author": "Cui", "year": "2010", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB11|cit8", "doi-asserted-by": "crossref", "first-page": "522", "DOI": "10.1136/ard.2009.118935", "article-title": "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)", "volume": "69", "author": "Dixon", "year": "2010", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB12|cit9", "doi-asserted-by": "crossref", "first-page": "893", "DOI": "10.1136/ard.2006.068304", "article-title": "Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study", "volume": "66", "author": "Furst", "year": "2007", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB13|cit10", "doi-asserted-by": "crossref", "first-page": "1403", "DOI": "10.1016/S0006-2952(03)00490-8", "article-title": "Regulation of proliferation, survival and apoptosis by members of the TNF superfamily", "volume": "66", "author": "Gaur", "year": "2003", "journal-title": "Biochem Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB48|cit11", "doi-asserted-by": "crossref", "first-page": "34", "DOI": "10.1002/art.1780390105", "article-title": "Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria", "volume": "39", "author": "van Gestel", "year": "1996", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB10|cit12", "doi-asserted-by": "crossref", "first-page": "768", "DOI": "10.1136/ard.47.9.768", "article-title": "Tumour Necrosis factor in synovial exudates", "volume": "47", "author": "di Giovine", "year": "1988", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB14|cit13", "first-page": "896", "article-title": "Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy", "volume": "63", "author": "Gomez-Puerta", "year": "2004", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB15|cit14", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1007/978-0-387-89520-8_1", "article-title": "Overview of TNF superfamily: a chest full of potential therapeutic targets", "volume": "647", "author": "Grewal", "year": "2009", "journal-title": "Adv Exp Med Biol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB16|cit15", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1080/03009740410000921", "article-title": "Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis", "volume": "33", "author": "Gudbrandsdottir", "year": "2004a", "journal-title": "Scand J Rheumatol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB17|cit16", "first-page": "118", "article-title": "TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis", "volume": "22", "author": "Gudbrandsdottir", "year": "2004b", "journal-title": "Clin Exp Rheumatol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB18|cit17", "first-page": "31", "article-title": "Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response", "volume": "33", "author": "Haraoui", "year": "2006", "journal-title": "J Rheumatol"}, {"issue": "2", "key": "10.1111/j.1476-5381.2010.01099.x-BIB19|cit18", "doi-asserted-by": "crossref", "first-page": "ii13", "DOI": "10.1136/ard.62.suppl_2.ii13", "article-title": "Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis", "volume": "62", "author": "Hochberg", "year": "2003", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB20|cit19", "doi-asserted-by": "crossref", "first-page": "1558", "DOI": "10.1093/rheumatology/kel149", "article-title": "Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register", "volume": "45", "author": "Hyrich", "year": "2006", "journal-title": "Rheumatology (Oxford)"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB21|cit20", "doi-asserted-by": "crossref", "first-page": "3217", "DOI": "10.1002/art.24913", "article-title": "The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study", "volume": "60", "author": "Klaasen", "year": "2009", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB22|cit21", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.2165/00003088-200746080-00002", "article-title": "Clinical pharmacokinetics and use of infliximab", "volume": "46", "author": "Klotz", "year": "2007", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB23|cit22", "doi-asserted-by": "crossref", "first-page": "R50", "DOI": "10.1186/ar2419", "article-title": "Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept", "volume": "10", "author": "Koczan", "year": "2008", "journal-title": "Arthritis Res Ther"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB24|cit23", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1080/03009740701607067", "article-title": "The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review", "volume": "36", "author": "Kristensen", "year": "2007", "journal-title": "Scand J Rheumatol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB25|cit24", "doi-asserted-by": "crossref", "first-page": "569", "DOI": "10.1002/art.24275", "article-title": "Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study", "volume": "61", "author": "Krzysiek", "year": "2009", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB26|cit25", "doi-asserted-by": "crossref", "first-page": "477", "DOI": "10.1016/S0898-6568(01)00262-5", "article-title": "TNF receptor subtype signalling: differences and cellular consequences", "volume": "14", "author": "MacEwan", "year": "2002", "journal-title": "Cell Signal"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB27|cit26", "doi-asserted-by": "crossref", "first-page": "1932", "DOI": "10.1016/S0140-6736(99)05246-0", "article-title": "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group", "volume": "354", "author": "Maini", "year": "1999", "journal-title": "Lancet"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB28|cit27", "doi-asserted-by": "crossref", "first-page": "3532", "DOI": "10.1093/hmg/ddn245", "article-title": "Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis", "volume": "17", "author": "Maxwell", "year": "2008", "journal-title": "Hum Mol Genet"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB29|cit28", "doi-asserted-by": "crossref", "first-page": "3279", "DOI": "10.1002/art.21306", "article-title": "Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial", "volume": "52", "author": "Mease", "year": "2005", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB30|cit29", "first-page": "712", "article-title": "Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept", "volume": "33", "author": "Mease", "year": "2006", "journal-title": "J Rheumatol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB31|cit30", "doi-asserted-by": "crossref", "first-page": "R128", "DOI": "10.1186/ar2017", "article-title": "Independent associations of anti-cyclical citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis", "volume": "8", "author": "Mewar", "year": "2006", "journal-title": "Arthritis Res Ther"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB32|cit31", "doi-asserted-by": "crossref", "first-page": "1248", "DOI": "10.1002/art.23447", "article-title": "Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab", "volume": "58", "author": "Mitoma", "year": "2008", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB33|cit32", "doi-asserted-by": "crossref", "first-page": "1335", "DOI": "10.1007/s10067-006-0520-y", "article-title": "Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis", "volume": "26", "author": "Morozzi", "year": "2007", "journal-title": "Clin Rheumatol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB34|cit33", "doi-asserted-by": "crossref", "first-page": "36", "DOI": "10.1016/j.jim.2009.06.009", "article-title": "Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis", "volume": "348", "author": "Palframan", "year": "2009", "journal-title": "J Immunol Methods"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB35|cit34", "doi-asserted-by": "crossref", "first-page": "644", "DOI": "10.1016/j.cgh.2008.03.014", "article-title": "Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials", "volume": "6", "author": "Peyrin-Biroulet", "year": "2008", "journal-title": "Clin Gastroenterol Hepatol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB38|cit35", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1136/ard.2007.084715", "article-title": "Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis", "volume": "68", "author": "Potter", "year": "2009", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB37|cit36", "doi-asserted-by": "crossref", "first-page": "1315", "DOI": "10.1136/ard.2009.117309", "article-title": "Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways", "volume": "69", "author": "Potter", "year": "2010", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB39|cit37", "doi-asserted-by": "crossref", "first-page": "1739", "DOI": "10.1136/ard.2008.092833", "article-title": "Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis", "volume": "68", "author": "Radstake", "year": "2009", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB40|cit38", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.1146/annurev.immunol.19.1.275", "article-title": "IgG Fc receptors", "volume": "19", "author": "Ravetch", "year": "2001", "journal-title": "Annu Rev Immunol"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB41|cit39", "doi-asserted-by": "crossref", "first-page": "3096", "DOI": "10.1002/art.22838", "article-title": "A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis", "volume": "56", "author": "Ruperto", "year": "2007", "journal-title": "Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB42|cit40", "doi-asserted-by": "crossref", "first-page": "119", "DOI": "10.1006/abio.2001.5380", "article-title": "Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore", "volume": "299", "author": "Santora", "year": "2001", "journal-title": "Anal Biochem"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB44|cit41", "doi-asserted-by": "crossref", "first-page": "418", "DOI": "10.1124/jpet.301.2.418", "article-title": "Binding and functional comparisons of two types of tumor necrosis factor antagonists", "volume": "301", "author": "Scallon", "year": "2002", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB43|cit42", "doi-asserted-by": "crossref", "first-page": "73", "DOI": "10.1016/j.molimm.2004.01.006", "article-title": "Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency", "volume": "41", "author": "Scallon", "year": "2004", "journal-title": "Mol Immunol"}, {"issue": "4", "key": "10.1111/j.1476-5381.2010.01099.x-BIB45|cit43", "doi-asserted-by": "crossref", "first-page": "S449", "DOI": "10.1093/clinids/8.Supplement_4.S449", "article-title": "Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity", "volume": "8", "author": "Schiff", "year": "1986", "journal-title": "Rev Infect Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB46|cit44", "doi-asserted-by": "crossref", "first-page": "49", "DOI": "10.1136/gut.2009.183095", "article-title": "Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis", "volume": "59", "author": "Seow", "year": "2010", "journal-title": "Gut"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB47|cit45", "doi-asserted-by": "crossref", "first-page": "548", "DOI": "10.1136/ard.2006.058248", "article-title": "Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis", "volume": "66", "author": "Tynjala", "year": "2007", "journal-title": "Ann Rheum Dis"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB9|cit46", "doi-asserted-by": "crossref", "first-page": "531", "DOI": "10.1136/ard.2008.089979", "article-title": "Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis", "volume": "68", "author": "de Vries", "year": "2009", "journal-title": "Ann Rheum Dis"}, {"issue": "1", "key": "10.1111/j.1476-5381.2010.01099.x-BIB49|cit47", "doi-asserted-by": "crossref", "first-page": "34", "DOI": "10.1016/j.semarthrit.2005.01.009", "article-title": "Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab", "volume": "34", "author": "Wallis", "year": "2005", "journal-title": "Semin Arthritis Rheum"}, {"key": "10.1111/j.1476-5381.2010.01099.x-BIB1|cit48", "doi-asserted-by": "crossref", "first-page": "351", "DOI": "10.1056/NEJMoa041884", "article-title": "Etanercept plus standard therapy for Wegener's granulomatosis", "volume": "352", "author": "Wegener's Granulomatosis Etanercept Trial (WGET) Research Group", "year": "2005", "journal-title": "N Engl J Med"}], "container-title": ["British Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1476-5381.2010.01099.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 19]], "date-time": "2017-06-19T15:36:28Z", "timestamp": 1497886588000}, "score": 19.86075, "subtitle": ["TNF inhibitors for rheumatoid arthritis"], "issued": {"date-parts": [[2011, 1, 21]]}, "references-count": 48, "journal-issue": {"published-print": {"date-parts": [[2011, 2]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1111/j.1476-5381.2010.01099.x", "relation": {"cites": []}, "ISSN": ["0007-1188"], "issn-type": [{"value": "0007-1188", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}